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1FOREWORD
PUTTING PEOPLE, HEALTH AND HUMAN RIGHTS AT THE CENTRE  
OF GLOBAL DRUG POLICY  
The world is failing to protect the health and human rights of people who  
use drugs.
One result of this failure is an HIV response that has left behind people who 
inject drugs. Globally, there was no decline in new HIV infections among 
people who inject drugs between 2010 and 2014. This goes against the  
global trend of declining new HIV infections.
Evidence supports the need for a shift in the global approach to drug 
use. In this report, Do no harm: health, human rights and people who use 
drugs, UNAIDS shows what works to reduce the impact of HIV and other 
harms related to drug use. Countries that have moved away from laws and 
policies that are harmful to people who use drugs and that have increased 
investment in harm reduction have reduced new HIV infections and improved 
health outcomes. These policies also deliver broader social benefits, such as 
lower levels of drug-related crime and reduced pressure on health-care and 
criminal justice systems.
However, despite the large body of scientific evidence, these approaches are 
far from universal. Millions of people who use or inject drugs continue to be 
criminalized and marginalized. Stigma and discrimination prevent their access 
to health care, harm reduction and legal services. Levels of drug use remain 
unchanged. 
In this report, UNAIDS calls for the global adoption of a people-centred, 
public health and human rights-based approach to drug use. 
The world cannot continue to ignore the evidence. Over the coming months, 
the United Nations General Assembly will have two opportunities to reflect 
on this evidence-informed approach. The United Nations General Assembly 
Special Session on the World Drug Problem, being held from 19 to 21 April 
2016, provides an opportunity to refocus international drug policies on their 
original goal—the health and well-being of humankind. Less than two months 
later, from 8 to 10 June, the General Assembly will meet again for the High-
Level Meeting on Ending AIDS, where stronger commitments are needed to 
ensure that the AIDS response does not continue to leave behind people who 
inject drugs. 
This is a unique opportunity to adopt a new course of action—to treat people 
who use drugs with dignity and respect; to provide them with equal access 
to health and social services; to greatly reduce the harms of drug use; and 
to contribute to the end of the AIDS epidemic and the achievement of the 
Sustainable Development Goals. 
Michel Sidibé
UNAIDS Executive Director
“IN FULL COMPLIANCE WITH HUMAN RIGHTS 
STANDARDS AND NORMS, THE UNITED NATIONS 
ADVOCATES A CAREFUL RE-BALANCING OF 
THE INTERNATIONAL POLICY ON CONTROLLED 
DRUGS. WE MUST CONSIDER ALTERNATIVES 
TO CRIMINALIZATION AND INCARCERATION OF 
PEOPLE WHO USE DRUGS AND FOCUS CRIMINAL 
JUSTICE EFFORTS ON THOSE INVOLVED IN SUPPLY. 
WE SHOULD INCREASE THE FOCUS ON PUBLIC 
HEALTH, PREVENTION, TREATMENT AND CARE, AS 
WELL AS ON ECONOMIC, SOCIAL AND CULTURAL 
STRATEGIES.”
UNITED NATIONS SECRETARY-GENERAL BAN KI-MOON 
26 JUNE 2015
3INTRODUCTION
The maxim primum non nocere—“Above all, do no harm”—calls for 
careful consideration of the harms that may result from our actions (1).
Global efforts to control narcotic drugs and psychotropic substances 
are based on the premise that the misuse of these substances can lead 
to serious harm to the individual and society. As countries gather at the 
United Nations General Assembly Special Session (UNGASS) on the 
World Drug Problem on 19–21 April 2016, more than a half century after 
the Single Convention on Narcotic Drugs was agreed, the harms caused 
by international drug control to people who use drugs require much 
greater attention.
The vast majority of the 246 million people who use drugs have been 
criminalized by national legislation and marginalized by society (2). 
Many have been traumatized by violence, imprisoned for possession of 
small quantities of drugs for personal use or coerced to undergo drug 
dependence treatment. Women who use drugs have been forced to 
undergo sterilization or abortions, separated from their children and 
denied public housing and other benefits.
As a result, people who use drugs, especially those who inject drugs, 
have been isolated and often denied the means to protect themselves 
from HIV, hepatitis C virus, tuberculosis and other infectious diseases. 
Among the estimated 12 million people who inject drugs globally, 1 in 
10 is living with HIV (3). Hundreds of thousands have been incarcerated 
in compulsory detention centres, including more than 455 000 in seven 
Asian countries (4). 
The tools and strategies required to improve the health and lives of 
people who use drugs are well known and readily available. Needle–
syringe programmes reduce the spread of HIV and other bloodborne 
viruses. Opioid substitution therapy and other evidence-informed forms 
of drug dependence treatment curb drug use, reduce vulnerability to 
infectious diseases and improve uptake of health and social services. 
Naloxone is an effective treatment for opioid drug overdoses and saves 
lives. Treatments for HIV, hepatitis C virus and tuberculosis greatly 
reduce morbidity and mortality. The United Nations Office on Drugs and 
Crime (UNODC), the World Health Organization (WHO) and UNAIDS 
recommend using these services within a comprehensive package of 
health interventions. Beyond the package, drug consumption rooms 
and heroin-assisted drug dependence treatment may deliver important 
benefits to the most marginalized and severely dependent people who 
inject drugs.
4An overwhelming body of evidence shows that these harm reduction 
approaches reduce the health, social and economic harms of drug 
use to individuals, communities and societies, and they do not cause 
increases in drug use. Harm reduction is also cost effective. For 
example, each dollar spent on Australia’s needle–syringe programme 
returns up to US$ 5.50 in averted health-care costs (5). By comparison, 
criminalization and incarceration appear expensive and ineffective. 
Criminalization has been shown to perpetuate risky forms of drug use, 
to increase the risk of illness (including HIV infection) among people 
who use drugs, to discourage people who use drugs from seeking 
health care, and to reinforce the marginalization by society of people 
who use drugs (6). In the United States of America, each dollar spent 
on incarceration of people who use drugs generates only US$ 0.33 in 
public safety gains (7, 8).
Maximization of the coverage and effectiveness of harm reduction 
requires an enabling legal and policy environment and the dedication 
of sufficient financial resources. Countries that have decriminalized or 
relaxed criminal penalties for drug possession and use have increased 
enrolments into drug dependence treatment, reduced criminal 
justice costs and improved the health of people who use drugs. For 
example, Portugal’s depenalization of the purchase, possession and 
consumption of small amounts of narcotic drugs, and expansion of 
the availability of harm reduction services, have coincided with a 95% 
decrease in the number of people who inject drugs diagnosed with HIV 
each year (9). In the Czech Republic, decriminalization of possession 
and use of small quantities of drugs combined with a relatively high 
coverage of harm reduction have been credited with bringing about 
remarkably low rates of HIV among people who inject drugs (10). In 
China, the expansion of needle–syringe programmes and methadone 
maintenance therapy has seen the proportion of HIV infections 
acquired through injecting drug use plummet from nearly 50% to less 
than 1 in 10 (11).
Cost-effectiveness of harm reduction and incarceration of people who use drugs
US$ 1 spent on 
harm reduction in 
Australia returns 
US$ 5.50 in averted 
health-care costs.
US$ 1 spent on the 
incarceration of people who 
use drugs in the United States 
of America generates US$ 
0.33 in public safety gains.
Sources: Kwon J et al. Estimating the cost-effectiveness of needle–syringe programs in Australia. AIDS 2012;26:2201–2210.
Przybylski R. Correctional and sentencing reform for drug offenders: research findings on selected key issues. Lakewood, CO: RKC Group; 2009 (http://www.ccjrc.
org/wp-content/uploads/2016/02/Correctional_and_Sentencing_Reform_for_Drug_Offenders.pdf.)
State of Oregon, Criminal Justice Commission. Report to the legislature. January 2007. (http://www.oregon.gov/v3replaced/docs/cjc2007reporttolegislature.pdf)
5These successes and others have fuelled a rising chorus for change. 
The International Narcotics Control Board has advised countries that 
international drug control conventions contain sufficient flexibilities for 
the scale-up of harm reduction within a balanced approach to drug 
control (12). WHO has called on countries to develop policies and 
laws that decriminalize drug use in order to reduce incarceration and 
improve coverage of harm reduction services (13). The United Nations 
Committee on Economic, Social and Cultural Rights, the United 
Nations Committee on the Rights of the Child, the United Nations High 
Commissioner for Human Rights and the Special Rapporteur on the 
Right to Health have all endorsed a harm reduction approach to drug 
use (14), and the United Nations General Assembly has stated that 
expansion of harm reduction will be critical to achieving international 
targets to reduce HIV infections among people who inject drugs (15).
Outside western Europe, North America and Oceania, however, few 
countries have achieved sufficient coverage of harm reduction services. 
In many middle-income countries with large populations of people who 
inject drugs, harm reduction is funded predominantly by international 
donors and private foundations. This heavy reliance on donor 
resources, combined with the retention of policies that criminalize 
and penalize people who use drugs, limits scale-up and threatens the 
sustainability of existing services.
Globally, low coverage of harm reduction programmes has translated 
into a lack of progress. There was no decline in the annual number of 
new HIV infections among people who inject drugs from 2010 to 2014 
(3). A global target to substantially reduce HIV transmission among 
people who inject drugs by 2015 has not been met. 
The Sustainable Development Goals agreed by the United Nations 
General Assembly in 2015 include new targets to achieve universal 
health coverage, to end the epidemics of HIV and tuberculosis, to 
combat hepatitis, and to strengthen the prevention and treatment of 
drug dependence by 2030. The world will struggle to achieve these 
goals unless substantially greater investments are made in the health of 
marginalized populations such as people who use drugs.
UNAIDS has developed a 2016–2021 strategy to put the world on 
track to ending AIDS as a public health threat by 2030. A critical target 
within this Fast-Track approach is the expansion of a combination of 
HIV prevention and harm reduction services to reach 90% of people 
who inject drugs by 2020. Achieving this target would require annual 
investment in outreach, needle–syringe distribution and opioid 
substitution therapy in low- and middle-income countries to increase to 
US$ 1.5 billion by 2020 (16).
Meanwhile, an estimated US$ 100 billion is spent each year to reduce 
the supply and demand of narcotic drugs (17). Aggressive policing 
and punishment have had little or no impact on the number of 
people using drugs. Country data collected by UNODC show that the 
6percentage of people who use illicit drugs has remained stable—
fluctuating between 4.6% and 5.2% of adults aged 15–64—since 
at least 2006 (2). Overly restrictive drug control policies also deny 
access to essential pain relief medicines to millions of women in 
labour, people with terminal cancer, people with late-stage AIDS 
and victims of violence and accidents.
The UNGASS on the World Drug Problem is an opportunity 
to refocus the international drug control system on its original 
goal—the health and well-being of humankind. UNAIDS calls 
on United Nations Member States to take on board five policy 
recommendations and 10 operational recommendations for a 
people-centred public health and human rights-based approach to 
drug use.
These recommendations are supported by the body of evidence 
contained within this report. They aim to treat people who use drugs 
with dignity and respect, to provide them with equal access to health 
and social services, to greatly reduce the harms of drug use, and to 
contribute to the end of the AIDS epidemic and the achievement of 
the Sustainable Development Goals.
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RECOGNIZE THAT THE OVERARCHING PURPOSE OF DRUG 
CONTROL IS FIRST AND FOREMOST TO ENSURE THE HEALTH, 
WELL-BEING AND SECURITY OF INDIVIDUALS, WHILE 
RESPECTING THEIR AGENCY AND HUMAN RIGHTS AT ALL TIMES. 
ENSURE ACCOUNTABILITY FOR THE DELIVERY OF HEALTH 
SERVICES FOR PEOPLE WHO USE DRUGS BY INCLUDING PUBLIC 
HEALTH AND HUMAN RIGHTS PILLARS IN THE FRAMEWORK OF 
THE UNGASS OUTCOME DOCUMENT THAT INCORPORATE CLEAR 
OBJECTIVES FOR REDUCING NEW HIV INFECTIONS AND PROTECT 
AND PROMOTE THE RIGHTS OF PEOPLE WHO INJECT DRUGS.
 
COMMIT TO FULLY IMPLEMENT HARM REDUCTION AND 
HIV SERVICES, AS OUTLINED IN THE WORLD HEALTH 
ORGANIZATION’S CONSOLIDATED GUIDELINES ON HIV 
PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY 
POPULATIONS.
 
COMMIT TO TREATING PEOPLE WHO USE DRUGS WITH 
SUPPORT AND CARE, RATHER THAN PUNISHMENT. UNAIDS 
BELIEVES THAT THIS OBJECTIVE CAN BE ACHIEVED ONLY BY 
IMPLEMENTING ALTERNATIVES TO CRIMINALIZATION, SUCH 
AS DECRIMINALIZATION AND STOPPING INCARCERATION OF 
PEOPLE FOR THE CONSUMPTION AND POSSESSION OF DRUGS 
FOR PERSONAL USE.
 
ENSURE INTEGRATION OF HIV SERVICES WITH OTHER HEALTH AND 
SOCIAL PROTECTION SERVICES FOR PEOPLE WHO USE DRUGS.
FIVE POLICY RECOMMENDATIONS
8T E N  O P E R AT I O N A L  R E C O M M E N D AT I O N S
1.  
Ensure that all people who inject drugs, including people in prisons 
and other closed settings, have access to harm reduction services to 
prevent HIV infection, including needle–syringe programmes, opioid 
substitution therapy and antiretroviral therapy. 
 
2.  
Ensure that all people who inject drugs and are living with HIV have 
access to life-saving antiretroviral therapy and other health services to 
manage tuberculosis, viral hepatitis and sexually transmitted infections. 
In addition, ensure adequate availability and access to opioids for 
medical use to reduce pain and suffering. 
 3.  
Ensure that all people who use drugs have access to non-coercive 
and evidence-informed drug dependence treatment consistent 
with international human rights standards and the Principles of Drug 
Dependence Treatment articulated by the United Nations Office 
on Drugs and Crime and the World Health Organization. All forms 
of compulsory drug and HIV testing and drug treatment should be 
replaced with voluntary schemes. The use of compulsory detention 
centres for people who use drugs should cease, and existing centres 
should be closed. 
 4.  
Adapt and reform laws to ensure people who use drugs do not face 
punitive sanctions for the use of drugs or possession of drugs for 
personal use. Countries should consider taking a range of measures, 
including alternatives to criminalization, incarceration, penalization and 
other penalties based solely on drug use or possession of drugs for 
personal use. These measures include decriminalization, steps to reduce 
incarceration, removal of administrative penalties and depenalization.   5.  
Ensure that the human rights of people who use drugs are not violated, 
by providing access to justice (including through legal services), 
prevention, treatment and other social services. Adopt smart policing 
measures to encourage people to access public health services.
96.  
Recognize that stigma and discrimination impede access to HIV 
prevention, treatment and other health and development services, and 
ensure that all people who use drugs are not discriminated against 
while accessing health, legal, education, employment and other social 
protection services.
7.  
Recognize that incarcerating people in prisons increases their risk of 
drug use, HIV infection and other health conditions and take steps to 
ensure that harm reduction and other health services are available in 
prisons in parallel with efforts to reduce the number of people being 
incarcerated for non-violent drug offences.
8.  
 Ensure widespread availability of naloxone among health workers,  
first responders, prison staff, enforcement officials and family  
members as a life-saving public health measure to enable timely  
and effective prevention of deaths from opioid overdose among  
people who use drugs.
9.  
 Support and empower community and civil society organizations, 
including organizations and networks of people who use drugs, in the 
design and delivery of HIV, health and social protection services.
10. 
 Undertake a rebalancing of investments in drug control to ensure 
that the resources needed for public health services are fully funded, 
including harm reduction for HIV infection, antiretroviral therapy, drug 
dependence treatment and treatment for hepatitis, tuberculosis and 
other health conditions.
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HIV AND PEOPLE WHO INJECT DRUGS: 
LACK OF GLOBAL PROGRESS
In 2011, when the United Nations General Assembly gathered for a 
High-Level Meeting on AIDS, United Nations Member States recognized 
that HIV prevention efforts had been inadequately focused on key 
populations at higher risk of HIV infection, including people who inject 
drugs. The resulting Political Declaration on HIV and AIDS included 
10 ambitious targets for 2015, including a pledge to reduce HIV 
transmission among people who inject drugs by 50% by 2015 (1).
Since the Political Declaration was agreed, the global AIDS response 
has achieved substantial progress, including increases in domestic and 
donor investment in the HIV responses in low- and middle-income 
countries, a rapid increase in the number of people living with HIV 
receiving antiretroviral therapy and substantial progress towards 
eliminating mother-to-child transmission of HIV, reducing the number 
of mothers dying from AIDS-related causes and reducing tuberculosis-
related deaths among people living with HIV (2). These results inspired 
even greater ambition—the Sustainable Development Goals agreed by 
the General Assembly in 2015 include a commitment to end the AIDS 
epidemic by 2030.
REGION INCIDENCE PER YEAR POPULATION SIZE ESTIMATE
Asia and the Pacific 1.4% [0.7–2.6%] 4 012 000 [2 796 000–5 302 000]
Latin America and the Caribbean 0.3% [0.1–0.7%] 721 000 [312 000–1 375 000]
Eastern and southern Africa 2.9% [1.0–19.5%] 333 000 [128 000–2 055 000]
Eastern Europe and central Asia 2.0% [1.1–3.8%] 3 159 000 [2 054 000–5 005 000] 
Middle East and North Africa 1.2% [0.5–4.4%] 462 000 [299 000–1 128 000]
Western and central Africa 1.4% [0.3–15.0%] 155 000 [32 000–1 484 000]
Western and central Europe 0.8% [0.4–1.4%] 800 000 [719 000–914 000]
North America 0.3% [0.1–0.5%] 2 104 000 [1 819 000–2 413 000]
Source: UNAIDS, 2016.
People who inject drugs: estimated population size and incidence of HIV infection, by region, 2014
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However, global progress against HIV has left behind many people who 
inject drugs. UNAIDS estimates that 140 000 [112 000–168 000] people 
who inject drugs were newly infected with HIV globally in 2014, and 
people who inject drugs and their sexual partners accounted for about 
30% of the people newly infected with HIV outside sub-Saharan Africa. 
Evidence available to UNAIDS suggests that there was no decline in the 
annual number of new HIV infections among people who inject drugs 
between 2010 and 2014. This lack of global progress obscures important 
differences among countries and regions.
These differences are most dramatic in Europe. In western and central 
Europe, where many countries have maintained high coverage of harm 
reduction programmes for more than a decade, the number of people 
who inject drugs newly diagnosed with HIV has steadily declined, from 
2161 in 2005 to 1126 in 2014 (3). The annual number of HIV cases among 
people who inject drugs is much higher in eastern Europe, where trends 
are dominated by the Russian Federation. Available data suggests 
there are at least 1.5 million people who inject drugs in the Russian 
Federation—nearly half of the region’s 3.2 million people who inject 
drugs. In 2007, the number of newly reported HIV cases among people 
who inject drugs in the Russian Federation (12 538) was similar to the 
number in the rest of eastern Europe (12 026). Since then, the trends in 
case reporting have diverged dramatically. According to the European 
Centre for Disease Prevention and Control, the scaling up of harm 
reduction programmes in several eastern European countries coincided 
with stabilization in newly reported HIV cases among people who inject 
drugs, followed by a reduction to less than 7000 in 2014. In the Russian 
Federation, where access to sterile needles and syringes is low and 
opioid substitution therapy remains illegal and unavailable, the number 
of people who inject drugs newly infected with HIV climbed to nearly 
22 500 in 2014 (4). In central Asia, data reported to UNAIDS suggest 
that Kyrgyzstan and Tajikistan are experiencing declines in the number 
of people who inject drugs newly infected with HIV, and the estimated 
infection rates in Azerbaijan and Kazakhstan are relatively stable.
Number of people who inject drugs reported to be newly diagnosed with HIV in Europe,* 2005–2014
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
25 000
20 000
15 000
10 000
5000
0
Russian Federation
Eastern Europe (excluding
Russian Federation)
Western and central Europe
* Subregional classification according to European Centre for Disease Control norms.
Sources: European Centre for Disease Control, Russian Federation AIDS Bureau.
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UNAIDS estimates that more than 4 million people inject drugs in Asia 
and the Pacific, where HIV prevalence within this key population in 2014 
was uniformly high, and eight of 19 countries reported that more than 
one in 10 people who inject drugs was living with HIV (5). In recent 
years, evidence of substantial reductions in the number of people 
newly infected with HIV in Bangladesh, Indonesia, Malaysia, Myanmar, 
Nepal and Viet Nam has been counterbalanced by a doubling new 
HIV infections among people who inject drugs in Pakistan and stable 
rates in Thailand. Data from India, where nearly 10% of the almost 2 
million people who inject drugs are living with HIV (6), suggest that 
injecting drug use is spreading beyond regions where use is well known 
and documented (7). In China, where the HIV prevalence among an 
estimated 1.9 million people who inject drugs is 6% (8), a steep decline 
in the proportion of all new HIV infections attributable to injecting drug 
use between 2003 and 2013 (9) suggests a decline in the rate of new 
HIV infections.
The growing importance of sub-Saharan Africa as a transit area for heroin 
smuggling has coincided with an increase in injecting drug use. Heroin 
use and injecting drug use has spread south along the Swahili coast and 
subsequently moved inland, following transport routes along trans-African 
highways (10, 11). Kenya, Madagascar, Mauritius, Mozambique, Nigeria, 
Senegal, South Africa and the United Republic of Tanzania are all home 
to many people who inject drugs. There are also significant populations 
of people who inject drugs among the island countries of the Indian 
Ocean. Although limited in scope, surveys among people who inject 
drugs in sub-Saharan Africa suggest high HIV prevalence. In Kenya, where 
HIV prevalence among people who inject drugs is about 18% versus 5.6% 
in the general population, low condom use and safe injecting practices 
exacerbate transmission (12). Surveys in western Africa found the HIV 
prevalence among people who inject drugs to be 4.2% in Nigeria (13), 
5.3% in Abidjan, Côte d’Ivoire (14) and 13.3% in Kinshasa, Democratic 
Republic of the Congo (15).
The United States of America is home to more than 90% of the estimated 
2 million people who inject drugs in North America. Heroin use has 
increased among men and women in most age groups and across 
all income levels in the United States, leading to a 286% increase in 
heroin-related overdose deaths from 2002 to 2013 (16). The number of 
prescription opioid pain medications and overdose deaths attributed to 
these medications also quadrupled over a 15-year period (17). These 
trends have coincided with an increase in hepatitis C virus infections and 
new outbreaks of HIV associated with injecting drug use (18). Despite 
these worrying trends, annual diagnoses of HIV infection attributed 
to injecting drug use nationally fell from 2010 to 2014 among both 
men (2115 to 1590) and women (1455 to 1045) (19). In Canada, where 
comprehensive harm reduction programmes in major cities reach a large 
proportion of the estimated 112 900 [90 000–135 800] people who inject 
drugs (20), national health authorities estimate that the number of people 
who inject drugs newly infected with HIV declined from 531 [380–680] in 
2011 to 270 [180–360] in 2014 (21).
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In Latin America and the Caribbean, there are limited data on people who 
inject drugs and HIV, and population size estimates in some countries 
may include substantial numbers of former injectors or people who use 
drugs but do not inject. Users of non-injecting drugs in the region appear 
to have higher HIV prevalence because of sexual risk behaviour. In Brazil, 
a 2011 survey of people who use drugs found low rates of low rates of 
condom use, as well as HIV testing and HIV prevalence of 5%—eight times 
higher than the general population (22). In Montevideo, Uruguay, 6.3% of 
people who smoke cocaine surveyed in 2012 were living with HIV; among 
the survey respondents who reported engaging in transactional sex within 
the last 12 months , HIV prevalence was 17.9% (23). In Argentina, the 
estimated proportion of new HIV infections among people who inject 
drugs decreased from 7.6% in 2005–2007 to 0.4% in 2011–2013 (24).
In the Middle East and North Africa, recent data on people who inject 
drugs are sparse. There is evidence of HIV epidemics among people who 
inject drugs in at least one third of the countries in the region, with HIV 
prevalence across the region estimated to be in the range of 10–15% (25). 
Data from North Africa are particularly concerning, with suggestions of 
steady incidence and rising prevalence in some settings (26). One of the 
highest rates of HIV prevalence in the world—87%—and hepatitis C virus 
prevalence of 94% were detected by a survey among 328 people who 
inject drugs in Tripoli, Libya, in 2010 (27).
Recent alarming outbreaks of HIV among populations of people who 
inject drugs have been detected across most regions—including Jalalpur 
Jattan, Pakistan (28); Indiana, United States (29); Kanpur, India (7); Athens, 
Greece (30); and Bucharest, Romania (31). This underscores the need to 
ensure access to comprehensive HIV prevention services, even in areas 
where the HIV prevalence among this key population is currently low.
Increases in heroin dependence and heroin-related overdose deaths in the United States of America, 2002–2013
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Reproduced from: Today’s heroin epidemic: more people at risk, multiple drugs abused. Atlanta: United States Centers for Disease Control and 
Prevention; 2015 (CDC Vital Signs).
Sources: National survey on drug use and health (NSDUH) 2002-2013; National Vital Statistics System, 2002-2013.
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HARM REDUCTION
Many of the 12 million people who inject drugs are unable or unwilling 
to stop, despite the many negative outcomes associated with drug 
use. The foundation of a rights-based, public-health approach to this 
reality is harm reduction: services, programmes and policies that seek to 
reduce the health, social and economic harms of drug use to individuals, 
communities and societies.
Elements of harm reduction have been documented as far back as the 
1920s, when people treated for dependence on opioids in the United 
Kingdom were prescribed heroin or morphine to ease their withdrawal 
symptoms (1). Similar challenges led to the development of methadone 
maintenance therapy in the United States in the 1960s (2). The first 
needle–syringe programmes were launched in the 1970s when the role 
of sharing injecting equipment in the transmission of hepatitis B was first 
understood. The rampant spread of HIV among people who inject drugs 
in the 1980s convinced many high-income countries to greatly expand 
their needle–syringe programmes (2).
In too many countries with large populations of people who inject 
drugs, however, harm reduction has not expanded beyond small-scale 
pilot schemes funded by external donors. Detractors claim that harm 
reduction promotes drug use despite evidence to the contrary. Despite 
the many political and ideological barriers, harm reduction approaches 
have persisted due to an inexorable fact: harm reduction works. It 
reduces the spread of HIV and other bloodborne viruses, it reduces drug 
dependence and drug use and it prevents overdose deaths.
The overwhelming body of evidence on the effectiveness of harm 
reduction is the basis for a comprehensive package of interventions 
recommended by WHO, UNODC and UNAIDS for preventing the 
spread of HIV and reducing other harms associated with drug use.
NEEDLE AND SYRINGE DISTRIBUTION
Needle–syringe programmes reduce the probability of transmission of 
HIV and other bloodborne diseases by lowering the rates of sharing of 
injecting equipment among people who inject drugs (3, 4). The provision 
of low dead-space syringes may also decrease HIV risk among injectors 
who continue to share needles (5). Well-designed needle–syringe 
programmes also provide information on and facilitate access to a range 
of services, including drug dependence treatment, health care and legal 
and social services.
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Decades of experience within dozens of countries supports the 
effectiveness of needle–syringe programmes (1,6). Across eight 
countries in eastern Europe and central Asia, a tripling of needle–syringe 
programme coverage between 2005 and 2010 reduced risk behaviour 
related to HIV and hepatitis C virus and reduced new infections (7). Many 
individual programmes have achieved outstanding results. Ten years of 
needle–syringe programming in Australia reduced the number of cases of 
HIV by up to 70% and reduced the number of cases of hepatitis C by up 
to 43% (8). In New York, a sharp decrease in new HIV infections among 
people who inject drugs between 1992 and 2012 has been attributed to 
the implementation and expansion of syringe exchange since 1992 (9). 
In 2003 the New York City mayor publicly noted that harm reduction did 
not lead to increased drug use and drug-related crime, as opponents had 
warned. This political support led to further programme expansion (10).
Costing US$ 23–71 per person per year, needle–syringe programmes 
are relatively inexpensive to implement and are much more affordable 
than the lifetime health-care costs required to treat a person living with 
HIV (11). Cost-effectiveness is even higher if we consider the combined 
reduction of HIV and hepatitis C infections (12). For example, each dollar 
spent on Australia’s needle–syringe programme between 2000 and 
2010 has an estimated lifetime return on investment of US$ 1.30–5.50 in 
averted health-care costs (8). Conversely, the absence of needle–syringe 
programmes is a common feature in explosive and expensive increases 
in HIV incidence in communities that use drugs, for example in India, the 
Philippines, Thailand and the US state of Indiana (11, 13).
* The first nine of these interventions are from: Technical guide for countries to set targets for universal access to HIV prevention, 
treatment and care for injecting drug users. Geneva: World Health Organization, United Nations Office on Drugs and Crime and 
Joint United Nations Programme on HIV/ AIDS; 2012. The tenth intervention was recommended in: Consolidated guidelines on HIV 
prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2014.
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DRUG DEPENDENCE TREATMENT
People who are dependent on narcotic drugs and who want to reduce 
or completely stop their drug use can benefit from drug dependence 
treatment such as opioid substitution therapy. Treatment is neither quick 
nor simple. Drug dependence is a chronic health condition. As with other 
chronic conditions, long-term and continued treatment is often required; 
and the affected people remain vulnerable to relapse throughout their 
lifetime (14).
Despite these challenges, systematic reviews of opioid substitution 
therapy (mostly methadone or buprenorphine maintenance therapy) 
have demonstrated its effectiveness in the reduction or complete 
cessation of the use of heroin and other opioids (15,16). WHO placed 
methadone and buprenorphine on its Model List of Essential Drugs in 
2005 (17), in 2009 urged countries to make maintenance therapy with 
these medicines the backbone of their treatment systems for opioid 
dependence (18).
Reducing injecting drug use through voluntary opioid substitution 
therapy yields individual and public health dividends. Methadone 
maintenance therapy has been associated with a 54% reduction in the 
risk of HIV infection within populations of people who inject drugs (19). 
It has been calculated that providing sufficient access to this critical 
component of harm reduction could prevent 130 000 new HIV infections 
outside sub-Saharan Africa every year (20).
Percentage of newly diagnosed HIV and AIDS cases attributed to injecting drug use, New York State, 1985–2012
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Substitution therapy has also been shown to decrease the risk of hepatitis 
C infection (21), to increase adherence to antiretroviral therapy for HIV 
(22), to lower out-of-pocket health expenditure (25) and to reduce 
opioid overdose risk by almost 90% (24). The scale-up of methadone 
maintenance therapy in diverse country contexts, including Portugal (25), 
Viet Nam (26) and New Zealand (27), has also been associated with a 
decrease in crimes committed by people who use drugs.
Opioid substitution therapy has been shown to be cost effective based 
solely on its ability to reduce HIV infections (19). Its cost-effectiveness 
substantially increases when its wider health, economic, psychological 
and social benefits, including reductions in the number and severity 
of relapses and reductions in crime and the costs of drug-related 
incarcerations, are considered (19).
The successful piloting of opioid substitution therapy in India led to 
the inclusion of the “management” of drug dependence and approval 
of the establishment of treatment centres in a 2014 amendment to 
the Narcotics Drugs and Psychotropic Substances Act (28). This policy 
change has facilitated the scaling up of the programme to more than 
200 treatment centres serving about 22 500 people who inject drugs 
(29). Opioid substitution therapy is provided in both community settings 
and also through government health facilities in collaboration with 
nongovernmental organizations.
OVERDOSE TREATMENT
Opioid overdose claims the lives of an estimated 70 000–100 000 people 
each year (30). Naloxone is an extremely effective treatment for opiod 
drug overdose (31). Naloxone is relatively inexpensive, and using it may 
result in a life saved. In most countries, however, naloxone is accessible 
only by prescription or through hospitals and ambulance crews, who 
may not reach a person in need until it is too late. WHO recommends 
Costs of needle–syringe programmes versus antiretroviral therapy
Source: Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 
2015;26:S5–11; Fast-Track update on investments needed in the AIDS response. Geneva: UNAIDS; 2016 (http://www.unaids.org/en/
resources/documents/2016/unaids_fast-track_update_investments_needed, accessed 6 April 2016).
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that people likely to witness an opioid overdose should have access 
to naloxone and be instructed in its use for emergency management 
of suspected opioid overdose. An analysis of the cost-effectiveness 
of naloxone found that, even in a worst-case scenario, where very few 
overdoses were witnessed and naloxone was used only rarely, naloxone 
distribution to heroin users remained cost effective (32).
Scotland in the United Kingdom has been a world leader in the expansion 
of the availability of naloxone. In response to rising drug-related deaths, 
the Take Home Naloxone programme began in November 2010 by 
providing naloxone kits and training to people at risk of opioid overdose, 
including prisoners upon their release, and to their close friends and family 
(33). During the first four years of the programme, more than 20 000 
naloxone kits were issued (34).
In the United States, heroin-related overdose deaths increased by 
286% from 2002 to 2013 (35). By September 2015, 43 of 50 states 
had passed legislation to provide naloxone to people who are likely to 
witness an overdose, including family members and caregivers of people 
who use drugs (36). In 38 states, pharmacies can provide naloxone 
without a prescription (36). In 2015, the United States Food and Drug 
Administration approved nasal spray formulations of naloxone, which are 
easier to administer than an injection (37).
DRUG CONSUMPTION ROOMS AND HEROIN-ASSISTED 
DRUG DEPENDENCE TREATMENT
Other harm reduction approaches being used within a strong public 
health approach to drug use include drug consumption rooms and heroin-
assisted dependence treatment. Drug consumption rooms in Copenhagen, 
Denmark, aim to reduce harms among the city’s most marginalized and 
hard-to-reach people who use drugs, their families and the surrounding 
community, and to move their clients towards abstinence. One such 
facility, called The Cloud, provides booths for injecting and smoking. 
Source: Community management of opioid overdose. Geneva: World Health Organization; 2014 (http://www.who.int/substance_abuse/publications/
management_opioid_overdose/en, accessed 6 April 2016).
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Injecting booths include sterile needles and syringes, a vein finder and 
a waste bin. Police do not interfere with people using the facility, and 
medically trained personnel are on hand to attend to overdoses and 
accidental injuries. An evaluation of the programme found a decrease 
in theft, an 80% reduction in unsafe disposal of drug paraphernalia, 
and calls from the surrounding community for the facility to expand 
its opening hours, as disturbances and public drug-taking decreased 
during opening hours but remained prevalent when the facility was 
closed (38).
Evaluations of a similar drug consumption room in Vancouver, Canada, 
called Insite, found that it reduces needle sharing, overdose risk, public 
injecting, drug-related litter and violence against women who inject 
drugs; promotes health care and drug dependence treatment; and 
does not lead to increased drug use or increased crime (39). A cost–
benefit and cost-effectiveness analysis of Insite found that it prevents an 
estimated 35 new cases of HIV and two to three deaths in the city per 
year, with a benefit to cost ratio of 5.12 to 1 (40).
Since the 1990s heroin-assisted drug dependence treatment has been 
piloted in several European countries and Canada as a second-line 
treatment for opioid-dependent people who have not responded to 
standard treatments such as methadone maintenance therapy (41). 
All injections are taken under direct medical or nursing supervision 
to ensure the person’s safety and prevent diversion of the drug 
(41). A review of six randomized controlled trials by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) found 
that heroin-assisted treatment reduced criminal activity and the use 
of “street” heroin and other drugs and improved physical and mental 
health. Heroin-assisted treatment is more expensive than methadone 
maintenance therapy, however, and its users have more serious adverse 
events. On balance, EMCDDA has determined that heroin-assisted 
treatment successfully delivers important benefits to people with severe 
heroin dependence, their families and society (41).
COMBINATION APPROACH
Each individual approach, when implemented properly, reduces harms 
related to drug use and does not encourage illicit drug use. Reviews 
of these programmes have also found that delivering combined 
services of harm reduction and treatment is even more effective and 
cost effective than piecemeal approaches (11). For example, including 
condom provision within harm reduction programmes can help reduce 
the transmission of HIV from people who inject drugs to their sexual 
partners. New York City’s integration of condom social marketing, 
methadone maintenance treatment and needle–syringe programmes 
has been associated with substantial decreases in sexual risk behaviour 
among people who inject drugs living with HIV (42). Routinely offering 
HIV testing to people who access needle–syringe services and drug 
dependence treatment services is essential to identify people living 
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with HIV as soon as possible after infection and then to offer immediate 
initiation of antiretroviral therapy. Numerous studies have shown that 
people living with HIV who inject drugs are more likely to remain on 
antiretroviral therapy if they access opioid substitution therapy (22, 43).
Countries that have adopted a comprehensive approach to harm 
reduction are delivering better health outcomes for people who inject 
drugs and more effective management of drug use and drug-related 
crime. China has made impressive progress in the scale-up of harm 
reduction services in recent years. Needle and syringe distribution has 
grown from a limited pilot in the early 2000s to a national programme 
that provided 180 needles and syringes per person who injects drugs 
per year in 2011, and to 204 needles and syringes per person who 
injects drugs per year in 2014 (44, 45). China’s free voluntary methadone 
programme is among the largest in the world, serving more than 184 000 
people—nearly 10% of people who inject drugs in China (46). 
The impact of the programme has been dramatic. People who inject 
drugs accounted for less than 8% of people newly diagnosed with HIV 
in 2013, compared with 44% in 2003 (47).
In the Islamic Republic of Iran, a tough anti-drug campaign was 
launched following the 1979 revolution. Individuals caught possessing 
drugs received fines, imprisonment and corporal punishment, and the 
death penalty was imposed for serious drug offences. Despite these 
measures, drug use and drug trafficking continued to increase. Growing 
recognition of the limits of enforcement, and the importance of the 
medical and social dimensions of drug use, resulted in improvements 
in drug dependence treatment and the expansion of needle–syringe 
distribution (48). Harm reduction programmes are implemented by 
both governmental and nongovernmental facilities. Nongovernmental 
organizations provide comprehensive harm reduction services through 
Percentage of new HIV diagnoses attributed to injecting drug use, China, 2003 and 2013
Source: Halving HIV transmission among people who inject drugs. Geneva: UNAIDS; 2014 (http://www.unaids.org/sites/default/files/media_asset/20141125_
Background_Note_Thematic_Segment_35PCB.pdf, accessed 6 April 2016)
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drop-in centres and referrals to public health-care facilities. Services 
include needle exchange, methadone maintenance, general medical 
care, voluntary counselling and testing for HIV, and the provision of 
food, clothes and other basic needs (49). In prisons, “triangular clinics” 
integrate services for treatment and prevention of sexually transmitted 
infections, injecting drug use and HIV (49). At the end of 2014, 81.5% of 
surveyed people who inject drugs reported the use of sterile injecting 
equipment the last time they injected (50). Newly reported HIV cases 
among people who inject drugs fell from a peak of 1897 in 2005 to 684 
in 2013 (50).
BARRIERS TO HARM REDUCTION
International drug control conventions contain sufficient flexibilities 
for the introduction of harm reduction within a balanced approach to 
drug use (51). The United Nations Committee on Economic, Social 
and Cultural Rights, the United Nations Committee on the Rights of 
the Child and the Special Rapporteur on the Right to Health have all 
endorsed the recommendations of WHO, UNAIDS and UNODC for 
a comprehensive harm reduction approach to drug use. The United 
Nations High Commissioner for Human Rights has recommended 
harm reduction approaches, the Human Rights Council has recognized 
the need for these programmes (52), and the United Nations General 
Assembly has called on countries to consider adopting and expanding 
harm reduction programmes in order to meet international targets to 
reduce the number of people who inject drugs newly infected with 
HIV (53). The Johns Hopkins–Lancet Commission on Drug Policy and 
Health has urged the General Assembly to ensure that harm reduction 
is explicitly named and endorsed as a central element of drug policy 
within the outcome document of its 2016 Special Session on the World 
Drug Problem (54). 
Number of newly reported HIV cases among people who inject drugs, Islamic Republic of Iran, 2005 and 2013
Source: Islamic Republic of Iran AIDS progress report on monitoring of the United Nations General Assembly Special Session on HIV and AIDS. Tehran: 
National AIDS Committee Secretariat, Ministry of Health and Medical Education, Islamic Republic of Iran; 2015 (http://www.unaids.org/sites/default/files/en/
dataanalysis/knowyourresponse/countryprogressreports/2014countries/IRN_narrative_report_2014_en.pdf, accessed 6 April 2016).
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Despite these endorsements and the availability of detailed guidelines 
for implementation, the provision of combination harm reduction 
programmes remains profoundly insufficient. In 2014 needle–syringe 
programmes were available in only 90 of the 158 countries where 
injecting drug use has been documented, and opioid substitution 
therapy was available in only 80 of these countries (14). 
Where services exist, coverage is often low. The average number of 
syringes and needles distributed per person who injects drugs per year 
in most countries remains well below the internationally recommended 
200. Only 15 countries report having met this coverage target for needle–
syringe programmes at least once in the past four rounds of HIV response 
progress reporting to UNAIDS (55), and only 26 countries indicated high 
levels of coverage (more than 40%) of opioid substitution therapy in 2014 (56). 
Women who inject drugs face particular challenges in accessing harm 
reduction services (57). Higher levels of stigma and discrimination 
and harmful gender norms translate to lower control over injecting 
and more frequently being “second on the needle” when injecting 
equipment is shared (58). Many women who inject drugs also engage 
in sex work, an overlap that is especially common in parts of eastern 
Europe and central Asia and is a growing concern in some Latin 
American countries, such as Mexico (57). Harm reduction programmes 
that tailor their services to meet women’s needs are rare (59).
Availability of needle–syringe exchange programmes and opioid substitution therapy, 2014
Both needle–syringe programmes and 
opioid substitution therapy available
Opioid substitution therapy only
Needle–syringe programmes only
Neither available
Not known
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf)
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Laws, policies and police practices restrict or prevent harm reduction 
scale-up in many countries. Criminal justice systems that use possession 
of drug paraphernalia or drug residue within injecting equipment as 
evidence of illegal drug possession or use are particularly disruptive 
to needle–syringe programmes (60). Syringe confiscation has been 
associated with increases in HIV infection among female sex workers 
who inject drugs (61). In parts of eastern Europe and central Asia, 
Needles and syringes distributed per person who injects drugs per year in selected countries, 2014 
or latest year available
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nongovernmental organizations report that police may consider 
needle–syringe distribution as promotion of illegal drug use, which 
leads to a high rate of turnover among outreach workers who fear 
they may be arrested for carrying injecting equipment (62). Police 
crackdowns on drug use, random urine drug screens and police 
surveillance of health-care and harm reduction services providers 
discourage people who use drugs from accessing these services (60). 
During Thailand’s “war on drugs” campaign, health-care workers 
reported that police pressured them to identify people suspected 
of drug use, which discouraged people who use drugs from seeking 
HIV tests, antiretroviral therapy and other health care (63,64). Laws 
and policies with a disproportionate impact on women who use drugs 
include those that make drug use a criterion for loss of child custody, 
forced or coerced sterilization or abortion, and denial of public housing 
and other benefits (59, 65).
In some countries, opioid substitution therapy is unavailable or illegal. 
Substitution therapy using methadone and buprenorphine is forbidden 
by law in the Russian Federation, which has one of the highest rates 
of opioid use in the world (66). In some countries where opioid 
substitution therapy is available, police reportedly target people using 
such services for drug arrests (64, 67, 68).
In Myanmar, sections of a nearly 100-year-old excise act that had made 
possession of needles and syringes illegal were repealed in 2015 (69). 
The leadership of the national AIDS programme in Myanmar and local 
United Nations officials described the change as a major step forward 
in the expansion of harm reduction services within a country where 
more than one quarter of HIV infections are caused by the sharing of 
injecting equipment (70). Additional legal changes to end compulsory 
registration of people who use drugs and to reduce criminal 
penalties for possession and use of small amounts of drugs are under 
consideration (69).
INVESTING IN HARM REDUCTION
Reaching sufficient numbers of people who inject drugs with a 
comprehensive package of harm reduction services by 2020 is a critical 
component of wider efforts to achieve the end of the AIDS epidemic 
by 2030. The UNAIDS 2016–2021 Strategy calls on countries to reach 
90% of people who inject drugs with a combination of HIV prevention 
and harm reduction services. Achieving this target would require 
annual investment in outreach, needle–syringe distribution and opioid 
substitution therapy in low- and middle-income countries to increase to 
US$ 1.5 billion by 2020 (71). Meanwhile, an estimated US$ 100 billion is 
spent each year to reduce the supply and demand of narcotic drugs (72).
Closing the financing gap will require far broader financial commitment, 
especially among middle-income countries with large populations of 
people who inject drugs. In many of these countries, harm reduction is 
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funded predominantly by international donors and private foundations. 
Heavy reliance on donor sources limits potential for scale-up, threatens 
the sustainability of existing services, and is often a symptom of 
insufficient political and public support for harm reduction.
In Belarus, an upper-middle-income country where up to one quarter 
of people who inject drugs are living with HIV, the financing of harm 
reduction is being steadily transitioned from the Global Fund to Fight 
AIDS, Tuberculosis and Malaria (Global Fund) to domestic sources. The 
concept note for a 2016–2018 Global Fund grant pledges to increase 
Belarusian Government funding for HIV services from 35% in 2016 to 
62% in 2018, followed by full Belarusian Government funding at the 
end of the grant (73). Within this transition, the Belarusian Government 
plans to use new social contracting mechanisms and local budgets to 
directly contract nongovernmental organizations to provide HIV services 
(73). The programme aims to expand HIV prevention services to 60% 
of people, including needle–syringe distribution to 45 000 people who 
inject drugs and opioid substitution therapy to 4900 people by the end 
of 2018 (73). The Eurasian Harm Reduction Network has praised the 
ambitious targets and the Belarusian Government’s commitment to fully 
fund harm reduction after 2018 (74).
Donor funding as percentage of total expenditure on harm reduction programmes for people inject drugs, 2012–2014
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ACTION AREAS
 • Scale up comprehensive combination harm reduction to reach 
UNAIDS Fast-Track Targets by 2020.
 • Ensure harm reduction programmes make specific efforts to reach 
women who inject drugs.
 • Ensure naloxone is made available to people likely to witness an 
opioid overdose.
 • Explore the use of drug consumption rooms and heroin-assisted drug 
dependence treatment for people with severe dependence.
 • Remove legal and policy barriers to harm reduction, including the 
consideration of injecting equipment and other drug paraphernalia as 
evidence of drug use, police monitoring of health and harm reduction 
facilities, and bans on the use of methadone and buprenorphine for 
opioid substitution therapy.
 • Increase domestic financing of harm reduction in low- and middle-
income countries.
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HEALTH CARE
Millions of people who use drugs are vulnerable to HIV, tuberculosis, 
hepatitis C virus and sexually transmitted infections. Hepatitis C virus is 
more resilient than HIV and is capable of surviving on drug preparation 
and injecting equipment for several days to weeks (1). Hepatitis C virus 
is thus easier to transmit through the sharing of injecting equipment. 
An estimated 10 million people who inject drugs have chronic hepatitis 
C virus infection (2), and in some countries the majority of new and 
existing hepatitis C virus infections have occurred as a result of sharing 
injecting equipment (3). An estimated 82.4% of people who inject drugs 
living with HIV are coinfected with hepatitis C virus (4). 
Compared with the general population, tuberculosis is more prevalent 
in people who inject drugs or who use other drugs (5). People living 
with HIV who inject drugs, especially in prison, are at particularly high 
risk of tuberculosis (5). Sexually transmitted infections among people 
who use drugs, including syphilis, gonorrhoea and chlamydia, have 
been associated with incarceration, crack cocaine use, transactional sex, 
multiple sexual partners and HIV infection (6). 
HIV and hepatitis C virus coinfection, globally, 2014
1 in 10
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Despite the high disease burden and the availability of evidence-
informed treatments, health systems rarely reach out to people who use 
drugs. Very low rates of HIV testing among people who inject drugs 
have been reported in Asia, the Pacific, sub-Saharan Africa, the Middle 
East and North Africa (7). Within the European Economic Area, 7 of 19 
countries have HIV testing rates among people who inject drugs below 
50% (8). The limited data available on antiretroviral therapy coverage 
among people living with HIV who inject drugs suggest that service 
uptake is much lower than among other people living with HIV. Among 
the countries that reported to UNODC in 2014, 22% described HIV 
treatment for people who inject drugs as unavailable or at low levels of 
coverage (9). In eastern Europe, people who inject drugs account for 
80% of HIV infections but only 20% of people on antiretroviral therapy 
(10). In the Russian Federation, people who inject drugs are estimated to 
account for 40% of people living with hepatitis C, but only 1% of people 
being treated for hepatitis C virus inject drugs (11).
BARRIERS TO HEALTH CARE
Drug control laws and policies have been shown to be among the 
largest obstacles in many countries. Criminalization of drug use is the 
most frequently reported barrier to HIV testing among people who use 
drugs in the European Economic Area (8). Fear of arrest was cited as a 
reason for discontinuing tuberculosis treatment among people who use 
drugs in China (12). In Mexico, the proximity of a police station to a local 
tuberculosis clinic was found to be a barrier to treatment adherence (13).
Discriminatory attitudes among health-care workers and within entire 
health systems turn away people who use drugs from services. In China, 
health-care workers have expressed reluctance to treat people with 
tuberculosis with a history of drug use due to fears they may not adhere 
to treatment. Poor adherence would reduce their health facility’s cure 
rate, which must meet a national target of 75% (12). People who inject 
drugs were initially excluded from hepatitis treatment due to concerns 
about adherence, increased susceptibility to side effects and reinfection 
(1). Analyses have since found that treatment of people who inject 
drugs for hepatitis C virus is both effective (13) and cost effective (14). 
WHO recommends focused hepatitis C virus screening for people who 
inject drugs, including repeated screening for people at ongoing risk 
of infection, and treatment combined with harm reduction for people 
found to have hepatitis C virus infection (15). WHO guidelines note that 
higher hepatitis C virus case-finding and treatment rates among people 
who use drugs would lead to greater population impacts and cost 
effectiveness (15).
The high cost of hepatitis C virus diagnosis and treatment has been a 
large barrier to service expansion (11). In the United States, 12-week 
courses of the branded versions of two of the most effective antiviral 
medications, sofosbuvir and daclatasvir, cost US$ 84 000 and US$  
63 000, respectively (16). Major progress has been made in recent 
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years to reduce the price of hepatitis C medicines in low- and middle-
income countries. Voluntary licensing agreements allow the production 
or import of generic versions of branded medicines to more than 100 
low-income countries, and some middle-income countries with large 
numbers of hepatitis C infections have negotiated price reductions. 
For example, a course of sofosbuvir now costs US$ 483 in India, and a 
course of daclatasvir costs US$ 525 in Egypt (17). Costs vary globally. 
In Brazil a course of sofosbuvir is approximately US$ 7000, in Spain and 
Portugal nearly US$ 28 000, and in the United Kingdom US$ 53 000 (17). 
Further and more widespread price reductions towards production costs 
for a sofosbuvir–daclatasvir combination estimated at US$ 200 per patient 
would facilitate efforts to increase the number of people treated (17). 
SERVICE INTEGRATION
Integration of services has consistently resulted in improved 
engagement, adherence and results. For example, people living with 
HIV who inject drugs and enrolled in methadone maintenance therapy 
are less likely to discontinue antiretroviral therapy and more likely to 
achieve viral suppression (18). People on opioid substitution therapy 
have also been shown to be highly adherent to hepatitis C virus 
treatment (19). Combining harm reduction services with hepatitis C 
virus treatment reduces the chance of hepatitis C virus reinfection (20). 
Service integration through co-location of interventions at a single site or 
through strong and coordinated linkage and referral between different 
service providers is recommended by WHO, UNODC and UNAIDS (21).
Costs of 12-week hepatitis C virus antiviral treatment courses in different countries, 2015
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In the United Republic of Tanzania, where HIV prevalence among 
people who inject drugs is quadruple the national rate and as high as 
62% among women who inject drugs (22), the importance of integration 
was understood soon after the country’s first methadone maintenance 
therapy clinic opened in 2011. An early methadone maintenance therapy 
patient at the Muhimbili National Hospital in Dar es Salaam died of 
tuberculosis, prompting concerns that led to establishment of an active 
tuberculosis case-finding programme and changes to the layout of the 
clinic to avoid transmission between patients and health-care workers. 
Among the first 150 methadone maintenance therapy patients, 4% had 
active pulmonary tuberculosis, which was roughly 23 times the national 
Tanzanian tuberculosis prevalence of 0.2% in 2011 (23). If passive case 
finding alone had continued, these people would have likely remained 
undiagnosed for a longer period of time, which may have led to 
additional tuberculosis infections and deaths (23).
In many settings, services are vertically organized, resourced and 
managed, and multidisciplinary care is lacking (24, 25). In 2010 less than 
a third of drug dependence treatment programmes in the United States 
offered HIV testing and counselling (26). In eastern Europe and central 
Asia, where cases of HIV among people who inject drugs continue to 
rise in many countries and multidrug-resistant tuberculosis rates are 
among the highest in the world, low coverage of opioid substitution 
therapy threatens efforts to integrate crucial health services and improve 
uptake (24).
In Estonia, where the rate of newly diagnosed HIV infections is among 
the highest in Europe (27), 60–80% of people on opioid substitution 
therapy in 2013 were living with HIV (28). Antiretroviral therapy is 
provided free of charge by the national health system, but in 2007 
less than 12% of people living with HIV who inject drugs were on 
treatment (29). Integration of harm reduction and antiretroviral therapy 
services was identified as the key to ensuring the sustainability of the 
national HIV prevention strategy (30). The opioid substitution therapy 
programme at West Tallinn Central Hospital now provides directly 
supervised dispensing of antiretroviral medicines (28).
In Portugal, individual health programmes have worked together to 
achieve co-located delivery of treatment services in locations that are 
convenient to people who inject drugs, with outreach teams acting as 
mediators among the services. The approach has achieved high HIV 
testing coverage among people at drug dependence treatment centres, 
and most people with tuberculosis know their HIV status (31).
In São Paulo, Brazil, the Program De Braços Abertos (Open Arms 
programme) provides comprehensive support to people who use crack 
cocaine, including employment, food, shelter and comprehensive 
health care (32). Because an estimated 5% of people who use drugs in 
Brazil are living with HIV (33), heath services include comprehensive HIV 
prevention, HIV testing and antiretroviral therapy. The use of fixed-dose-
combination antiretrovirals has improved treatment adhesion and health 
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outcomes. The success of this low-threshold, comprehensive approach 
has led to its replication in other Brazilian cities as part of the Ministry of 
Justice’s National Policy on Drugs (32).  
ACCESS TO ESSENTIAL CONTROLLED MEDICINES TO 
REDUCE PAIN AND SUFFERING
The Single Convention on Narcotic Drugs confirms that the medical use 
of narcotic drugs is “indispensable for the relief of pain and suffering 
and that adequate provision must be made to ensure the availability 
of narcotic drugs for such purposes”. The United Nations Committee 
on Economic, Social and Cultural Rights has described the availability 
of essential medicines, including opioids, as an essential element of 
the right to health and has warned that states are obligated to provide 
access to these medications, regardless of resource constraints (34). 
Palliative care—the provision of pain and symptom relief for people 
facing life-limiting illnesses—has been described by the World Health 
Assembly as fundamental to improving the quality of life, well-being, 
comfort and human dignity of terminally ill people (35).
Efforts by countries to meet their obligations within international drug 
control conventions to prevent the diversion, trafficking and misuse of 
controlled substances have limited the availability of essential medicines 
used to reduce pain and suffering (36). Approximately 5.5 billion people, 
or three quarters of the world’s population, have inadequate access to 
opioid analgesics (37). These drugs are simply unavailable to the vast 
majority of people outside high-income countries. For example, it has 
been estimated that 92% of the world’s morphine is consumed by 17% 
of the world’s population, primarily in North America, western Europe 
and Oceania (37).
As a result, every year tens of millions of people are not treated 
adequately for moderate or severe pain, including millions of women 
in labour, 5.5 million people with terminal cancer, 1 million people with 
late-stage AIDS and 800 000 victims of violence and accidents (38). 
At least 13 low- and middle-income countries—Burkina Faso, Burundi, 
Cambodia, Central African Republic, Chad, Côte d’Ivoire, Ethiopia, 
Haiti, Malawi, Mali, Niger, Nigeria and Rwanda—do not have sufficient 
supplies of opioids to treat 1% of their people with terminal cancer and 
people dying of AIDS-related diseases (39). Concerns over the diversion 
of methadone and other medicines used to treat dependence on heroin 
have also greatly limited the global expansion of opioid substitution 
therapy.
WHO has called on countries to ensure that national drug control 
policies recognize that controlled medicines, especially those on the 
WHO Model List of Essential Medicines, are necessary for medical and 
scientific purposes and that regulatory restrictions should be balanced 
with enabling policies that build the capacity of health professionals to 
manage proper use of these medicines, and to promote widespread 
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understanding of the therapeutic usefulness of controlled medicines 
and their responsible use, while preventing the development of drug 
use disorders and dependence associated with prescription drug use 
(36). The Johns Hopkins–Lancet Commission on Drug Policy and Health 
has called for WHO to be provided with sufficient resources to assist 
the International Narcotics Control Board in using the best science to 
determine the level of need for controlled drugs in all countries (40).
Colombia, Jordan, Romania, Uganda and Viet Nam have undertaken 
comprehensive reform programmes to improve access to palliative care 
(39). Leaders from the medical community in these countries worked with 
nongovernmental organizations and their own governments to assess 
what barriers exist to access to pain treatment, and to address these 
barriers through policy development, law reform, improving the education 
of health-care workers and strengthening drug supply systems (39).
UNODC has called for specific efforts to improve the ability of low- and 
middle-income countries to improve availability of opioid analgesics at 
affordable prices and to develop supervision systems that can detect 
illegal manufacture, over-prescription, unjustified sale or supply and 
diversion of controlled substances (41). WHO has stressed that finding 
the right balance between the control and access of opioid analgesics 
and other narcotic drugs will be critical to achieving public health targets 
within the Sustainable Development Goals (36).
ACTION AREAS
 • Take specific steps to address discriminatory attitudes among health-
care workers and remove structural barriers to the provision of health 
services to people who use drugs.
 • Ensure that treatments for HIV, tuberculosis and hepatitis C virus are 
affordable and readily available to people who use drugs.
 • Integrate health-care services with harm reduction services to improve 
engagement, adherence and results.
 • Ensure that opioid analgesics are affordable and available to all people 
who need them.
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“... in many societies people who use drugs are invisible, stigmatized 
or demonized. And history teaches us that when this happens—
when a group of people are invisible, stigmatized or demonized—
widespread human rights abuse often follows.”
Paul Hunt, United Nations Special Rapporteur on the Right to the Highest 
Attainable Standard of Health, 2002–2008
MARGINALIZATION OF PEOPLE WHO USE DRUGS
The preamble of the Single Convention on Narcotic Drugs describes 
dependence on narcotic drugs as a “serious evil for the individual” and 
“fraught with social and economic danger to mankind”. Community 
advocacy organizations have denounced such language as emblematic 
of the demonization of people who use drugs and the stigma and 
discrimination they face in their daily lives (1).
The exclusion and marginalization of people who use drugs has been 
acknowledged as one of several unfortunate consequences of the 
international drug control system (2). Studies of public perceptions of 
people who use drugs confirm that negative attitudes towards people 
who use drugs have been established during decades of the global war 
on drugs. One survey in the United Kingdom found that nearly half of 
respondents felt that people with a history of drug dependence were a 
burden on society, more than 40% said they would not want a person 
who has been dependent on drugs to be their neighbour, and about a 
third said it would be foolish to enter into a serious personal relationship 
with a person who had been dependent on narcotic drugs, even if that 
person appeared to be fully recovered (3).
Civil society organizations of people who use drugs describe pejorative 
terms such as “junkie” and “addict” commonly used in news media as 
hate speech that dehumanizes and stereotypes them as unpredictable, 
violent and unable to exercise agency and self-determination (4). 
Such beliefs weaken human rights safeguards and create barriers 
to employment, health care and social services. These barriers are 
even larger when people who use drugs internalize societal stigma. 
Judgemental feelings among health-care providers have been linked to 
lower-quality health care and lower health outcomes (5, 6). Nearly one 
quarter of people who use drugs surveyed in the United States reported 
they had been prevented from obtaining medical care because of their 
drug use, and one third said they had been denied housing because 
other people knew about their drug use (7).
STIGMA, DISCRIMINATION AND PUNISHMENT
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DISCRIMINATORY LAWS AND POLICIES
In many countries, laws, policies and other structural barriers facilitate 
discrimination of people with a history of drug use. In China, individuals 
determined by law enforcement to be dependent on heroin or other nar-
cotic drugs are permanently registered in a Chinese Government tracking 
system, even if they successfully undergo drug dependence treatment. 
Registered people report being ostracized and shunned once their history 
of drug use is discovered by others, and they express little hope of estab-
lishing a non-stigmatized, non-drug-using identity, even after undergoing 
drug dependence treatment and achieving sustained abstinence (8). As a 
result, unregistered people who use drugs are reluctant to seek treatment 
at Chinese Government–sponsored facilities (8). Many countries in eastern 
Europe and central Asia maintain similar “narcological registers”.
In the United States, federal law calls for people with drug-related 
convictions, including for personal possession and use, to be denied 
housing assistance, nutritional support, cash transfers, and grants and 
loans for higher education (9). Individuals coming out of prison for drug-
related crimes are thus denied social support services at a time when they 
may need it the most, increasing the likelihood that they will drop out of 
drug dependence treatment, struggle to find employment and suffer from 
food insecurity (10). Former prisoners who live in states that fully enforce 
the federal ban on nutritional support are more likely to report having 
gone an entire day without eating than those who live in states that do 
not enforce the ban. Furthermore, a study showed that people who did 
not eat for an entire day were more likely to engage in risky behaviour, 
such as using alcohol, heroin or cocaine before sex or exchanging sex 
for money (11). Similar legislation in Ontario, Canada, denying disability 
benefits to people dependent on drugs or alcohol was judged to be 
discriminatory and struck down by a court of appeals in 2010 (12).
DISCRIMINATION FACED BY WOMEN AND MINORITIES
Women who use drugs, especially those who inject drugs, face higher 
levels of stigma, discrimination and vulnerability to harm than their male 
counterparts (13). Hostile attitudes against women who use drugs and 
alcohol have been linked to higher rates of physical and sexual assault 
(14). In Georgia, more than 80% of women who use drugs reported 
experiencing violence in their own homes (15). A survey on violence 
against women in the Russian Federation found that 21% of respondents 
felt that a woman’s drug or alcohol addiction was a valid reason for 
her husband to beat her (16). Women who inject drugs and who have 
experienced sexual violence are more likely to be living with HIV than 
other women who inject drugs (17). Despite this, women who use 
drugs often have limited access to effective health and drug treatment 
services that take into account their specific needs and circumstances 
(18). Mothers with a history of drug use often fear to access health and 
social services due to legislation that may declare them unfit to parent. 
Pregnant women who use drugs may be pressured to have abortions or 
to give up their newborn infants (18).
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“Because drugs, and people who use them, are criminalized, people 
who use drugs are dehumanized, are judged to be criminals, and 
are understood as dangerous, deviant and socially disruptive. It 
is these understandings that result in people who use drugs being 
endemically discriminated against, and it is these perceptions that 
inform systemic violence and human rights violations perpetrated 
against people who use drugs. Fear and hatred of people who use 
drugs—drug-user phobia—is rife, and is rarely challenged.”
International Network of People Who Use Drugs, submission to the Civil Society 
Task Force to UNGASS on the World Drug Problem 2016
Evidence suggests that racial minorities also face higher levels of stigma 
and discrimination, including disproportionate targeting by drug-related 
law enforcement. In the United States, African-American and Hispanic 
people are significantly more likely to be stopped and searched, 
arrested, prosecuted, convicted and incarcerated for drug offences, even 
though their rates of drug dealing and drug use are almost identical to 
those of the rest of the population (19). Americans of African descent 
are more than 10 times more likely than Americans of European descent 
to be imprisoned for a drug-related offence; similar overrepresentation 
of ethnic minorities in prisons has been documented in other countries, 
including Australia and Canada (20). As a result, legislation that limits 
access to social services by people convicted of drug-related offences 
has a greater impact on ethnic minorities (10).
The United Nations High Commissioner for Human Rights has described 
the increased vulnerability arising from a vicious circle of criminalization, 
discrimination and denial of social services as an important factor in 
some countries’ decisions to decriminalize or depenalize personal use 
and possession of drugs. Community advocates have called for the 
repeal of legislation that reinforces stigma and discrimination of people 
who use drugs, and for the establishment of programmes that facilitate 
interaction between recovering drug users and the communities where 
they live in order to foster more constructive perceptions (3, 21).
DISPROPORTIONATE DRUG ENFORCEMENT MEASURES
The decades-long effort to disrupt the sale and purchase of narcotic 
substances for recreational use has pushed this market underground, 
where it is controlled by highly organized criminal organizations 
and gangs that have contributed to rising levels of violence in many 
countries, including widespread killings and disappearances (2 ,22). In 
response, drug-control legislation has grown increasingly severe, and 
anti-drug law enforcement has become increasingly militarized (23). 
People who use drugs are caught in the crossfire of this escalating war, 
and a disproportionate amount of the collateral damage is inflicted on 
women, children and ethnic minorities (24).
Efforts by some countries to get tough on drugs have included the 
imposition of stiff and sometimes mandatory minimum penalties 
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for drug-related crimes, including personal possession and use. For 
example, Tunisia imposes a minimum mandatory sentence of one year 
in prison on any person found guilty of use and possession of an illegal 
drug, including cannabis (25). Such legislation tends to have a particular 
impact on women and young people. Women are more likely to exist at 
the lower levels of the drug trade, working as drug cultivators, low-level 
dealers or couriers (26). People who use drugs and small-time street 
dealers are easier to find and apprehend than drug cartel kingpins. 
Young people arrested for drug possession have been pressured 
by police to act as confidential informants and to play roles in life-
threatening “sting” operations (27).
Crackdowns on narcotic drug use are too often accompanied by police 
violence against people who use drugs (28). Among the worst cases 
are reports of extrajudicial killings during the height of Thailand’s war 
on drugs in 2003 (29). A recent study found that nearly half the people 
who inject drugs surveyed in Bangkok in 2011 reported having been 
beaten by the police (30). Civil society documentation of police violence 
and intimidation against women who use drugs in eastern Europe 
and central Asia in 2013 included sexual abuse, beatings, humiliation, 
torture, blackmail and extortion (31).
The huge numbers of people arrested and detained for possession 
or use of small amounts of drugs have put immense strain on criminal 
justice systems, in some countries resulting in prolonged pre-trial 
detention (21) and a compromised ability to adhere to minimum 
standards of due process (32). The United Nations Special Rapporteur 
on Torture has documented numerous cases of torture—including 
violence and the withholding of opioid substitution therapy—against 
people detained for drug-related offences to extract confessions or 
obtain information about other drug users or traffickers (33).
PRISONS OVERCROWDED WITH PEOPLE WHO USE DRUGS
Severe punishments for drug-related crimes have also contributed 
to a global rise in incarceration and the overcrowding of prisons in 
many countries, which can lead to violations of prisoners’ rights to be 
treated with humanity and dignity (21). The Working Group on Arbitrary 
Detention has called on countries to ensure that sentences for drug-
related offences are proportionate to the nature of the crimes (24) and 
to remove legislation that denies people convicted of drug-related 
crimes the opportunities to be considered for suspended sentence, 
parole, pardon or amnesty that are available to people convicted of 
different crimes (34).
In some cases, being caught in possession of relatively small amounts 
of drugs leads to harsher punishments than those for murder, rape, 
kidnapping or bank robbery (21). In 2015, 33 countries or territories 
had laws prescribing the death penalty for drug-related offences, and 
since 2010 executions for drug offences occurred in at least seven 
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countries (35). For example, in Singapore, a 19-year-old man working as 
a courier for a drug dealer was sentenced to death in 2008 after being 
arrested with 47 grams of heroin in his possession. The death penalty 
is allowable under international law only for the “most serious crimes”, 
and the Human Rights Council has determined that drug-related 
offences do not meet this threshold (21). Following a high-profile legal 
challenge and advocacy from human rights groups, Singapore amended 
its Misuse of Drugs Act in 2012, and the sentence was reduced to life 
imprisonment (36).
Although the death penalty remains in force in Singapore for other 
drug-related offences, the change is part of a larger trend of countries 
stopping or reducing the use of the death penalty. Kyrgyzstan, the 
Philippines and Uzbekistan have abolished the death penalty for all 
offences, including drugs. Tajikistan limited the number of crimes 
punishable by death in 2004, removing drug offences from the list. 
Jordan has reduced the punishment for certain categories of drug crimes 
from the death penalty to life imprisonment (37).
COMPULSORY DETENTION AND TREATMENT
Approximately 27 million people who use drugs suffer from problem 
drug use, including drug-use disorders or drug dependence, and may 
benefit from treatment (38). More than 200 million other people who 
use drugs worldwide have no such need of treatment. Large numbers, 
however, are compelled to enter drug dependence treatment in ways 
that infringe on their human rights. A particularly grave concern is the 
hundreds of thousands of people who use drugs who are incarcerated 
in compulsory detention centres within at least 17 countries in Asia and 
Latin America (39, 40).
Compulsory or involuntary medical treatment of any kind is justified only 
as a last resort and for the shortest period of time necessary when strict 
criteria are met, including the presence of an immediate or imminent 
risk to the health of the patient or to the security of society (41). A set 
of principles issued jointly by WHO and UNODC stresses that drug 
dependence treatment, whether psychosocial or pharmacological, 
should not be forced on people (42).
In some countries, the decision-making process for sending people to 
compulsory drug detention facilities occurs outside the court system, 
a deprivation of liberty that violates the minimum standards of due 
process within the International Covenant on Civil and Political Rights 
(43). In other countries, courts give the accused a choice between a 
criminal conviction and a prison sentence, or a suspended sentence 
that will be dismissed if the individual completes a community 
drug dependence treatment programme. The United Nations High 
Commissioner for Human Rights has stated that the level of coercion 
within these “drug courts” may overstep an individual’s right to refuse 
medical treatment (21). The Working Group on Arbitrary Detention 
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has stated that such diversion into rehabilitation must not delay 
a determination of criminal responsibility (32), and that when the 
treatment option is undertaken under no circumstances may it extend 
beyond the period of the criminal sentence (21).
Long-term residential treatment of drug dependence without a 
person’s consent is essentially a form of low-security imprisonment (41). 
Proponents of compulsory detention centres argue they are a response 
not only to an individual’s drug dependence but also to a complex social 
problem that affects entire communities, and that the centres provide 
drug dependence treatment, educational programmes, job skills training 
programmes, physical exercise routines and opportunities for manual 
work in a safe, isolated environment (44).
The United Nations High Commissioner for Human Rights, the United 
Nations Special Rapporteur on Torture and the United Nations 
Special Rapporteur on the Right to Health have described numerous 
human rights concerns regarding the conditions within the centres 
and the drug dependence treatment provided. The treatment is not 
evidence-based and is conducted en masse, disregarding the need 
for individual informed consent and often provided without the aid or 
supervision of trained medical professionals. Centres typically subject 
detainees to long hours of physically strenuous exercise, physical and 
verbal abuse, beatings, solitary confinement and enforced labour 
(21). Former detainees have described specific accounts of ineffective 
treatment, forced labour, torture and other rights violations shortly after 
their release (45). Twelve United Nations organizations issued a joint 
statement in 2012 on compulsory drug detention and rehabilitation 
centres, calling for their closure and replacement with voluntary, 
evidence-informed and rights-based health and social services in the 
community.
Mounting concerns led to national policy reviews and transition plans in 
a number of Asian countries (46). Malaysia has been a pioneer of efforts 
to convert compulsory centres into facilities that provide voluntary, 
comprehensive and client-centred drug dependence treatment and 
support services, including methadone maintenance therapy (47). 
Health services at these “Cure and Care” centres include voluntary HIV 
counselling and testing, antiretroviral therapy, and testing and treatment 
for tuberculosis and hepatitis B and C (48). In Viet Nam, the Drug 
Rehabilitation Reform Plan commits to “gradually reducing compulsory 
treatment with an appropriate plan”. Although there is no commitment 
to end compulsory detention within the Plan, there is acknowledgement 
of its shortcomings, and a clear path for scaling down this approach and 
scaling up evidence-based drug dependence treatment.
Comparative evaluations of compulsory and voluntary approaches 
make a strong case for accelerating the transition to voluntary drug 
dependence treatment. In Malaysia, a comparative study found that 50% 
of people in compulsory detention centres relapse within a month of 
release, and all relapse within a year, whereas less than 40% of people 
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treated in Cure and Care centres relapse within a year (49). In addition, 
Malaysia’s National Anti-Drugs Agency reported that the annual cost of 
detaining one person in a rehabilitation centre is more than four times 
higher than the annual cost of treating one voluntary patient at a Cure and 
Care centre (50).
In Viet Nam, the cost effectiveness of compulsory detention centres 
and community-based voluntary methadone maintenance therapy was 
compared using three years of programme data and patient surveys from 
the northern port city of Hai Phong. The study found that people who 
underwent compulsory detention and rehabilitation were three times more 
likely than people on methadone maintenance therapy to test positive for 
heroin use and 3.3 times more likely to report the use of other narcotic 
drugs. Former centre residents were 5.6 times more likely to engage in 
illegal activities and nearly 7 times more likely to report HIV-related risk 
behaviour compared with people on methadone maintenance therapy. The 
cost of detaining an individual in a compulsory centre was 2.5 times higher 
than the cost of one year of methadone maintenance therapy (51).
Despite the efforts of a few countries to experiment with alternatives to 
compulsory detention centres, none appears to be phasing out such 
institutions. Among seven countries in Asia with available data, 455 814 
people who use drugs remained incarcerated in compulsory detention 
centres in 2014 (52). The number of detainees in these countries has 
decreased by just 4% since 2012, underscoring the urgent need for 
accelerating transition to voluntary community-based treatment and services. 
Percentage of people who tested positive for heroin use* among former residents of compulsory detention 
centres and methadone maintenance therapy patients, Hai Phong, Viet Nam, 2009–2013 
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COUNTRY 2012 2013 2014
Cambodia 2600 2713 3249
China 319 000 319 000 319 000
Lao People’s Democratic Republic 3915 4718 5339
Malaysia 5473 5136 5753
Philippines 2744 3266 4392
Thailand 112 589 131 496 96 680
Viet Nam 27 920 29 273 21 401
Total 474 241 495 602 455 814
Source: Country presentations. Third Regional Consultation on Compulsory Centres for Drug Users in Asia and the Pacific, 21–23 September 2015, Manila, 
Philippines. 
Number of people in compulsory detention centres for drug users in seven Asian countries, 2012–2014
Outside Asia, several countries in Latin America—including Brazil, 
Ecuador, Guatemala, Peru, Uruguay and Mexico—use some form of 
compulsory drug rehabilitation or are reported to be considering such 
an approach (40). The Russian Federation is reportedly considering the 
establishment of labour camps for hundreds of thousands of people who 
use drugs who are normally sent to prison (53).
The slow progress towards rights-based and evidence-informed 
responses to drug use and drug dependence was acknowledged at the 
Third Regional Consultation on Compulsory Centres for Drug Users in 
Asia and the Pacific, held on 21–23 September 2015 in Manila. Countries 
struggling to build momentum for change have highlighted numerous 
challenges, including growing use of amphetamine-type stimulants, a 
lack of human resources trained in evidence-based approaches, and 
the poor quality of programme monitoring and evaluation systems 
to assess the progress of transition (46). Government delegations 
from nine countries in the region, civil society, technical experts and 
United Nations system agency representatives agreed on a set of 
recommendations to accelerate transition from compulsory centres to 
voluntary, community-based drug dependence treatment and services. 
These recommendations included the establishment within countries 
of multisectoral decision-making committees with participation of 
civil society and communities of people who use drugs; multisectoral 
and participatory reviews of existing legal and policy frameworks; 
development of national transition plans with clear objectives, activities 
and timelines; strengthening the capacities of key government sectors 
and civil society to scale up voluntary, community-based treatment and 
services; and annual monitoring and reporting of progress.
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ACTION AREAS
 • Repeal legislation that facilitates stigma and discrimination of people 
who use drugs and denies them public and social services based solely 
on their past or present drug use.
 • Ensure that drug-related laws and policies do not discriminate against 
women who use drugs and ethnic minorities.
 • End the use of the death penalty for drug-related offences.
 • End the practice of compulsory detention and treatment of people who 
use drugs.
 • Ensure that drug courts do not infringe on a person’s rights to refuse 
medical treatment.
 • Incorporate human rights safeguards within drug control laws and drug-
related law enforcement.
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PRISONS
The Basic Principles for the Treatment of Prisoners adopted by the United 
Nations General Assembly in 1990 state that all prisoners should have 
access to the equivalent health services available in the country without 
discrimination on the grounds of their legal situation. The “Nelson 
Mandela Rules” for treatment of people in prison agreed within the 
United Nations in 2015 emphasize that the provision of health care for 
prisoners is a governmental responsibility. They also clarify that health care 
for prisoners should be free of charge, provided without discrimination 
on the grounds of legal status, and organized in close cooperation 
with a country’s public health system in a way that ensures continuity of 
treatment and care for HIV, tuberculosis, other infectious diseases and 
drug dependence (1).
DRUG USE AND HARM REDUCTION IN PRISONS
UNODC estimates that one in three people in prison have used drugs at 
least once while incarcerated, with approximately one in eight reporting 
drug use during the previous month (2). An estimated 1 in 10 people in 
prison have used heroin at some point during their incarceration, and 
small-scale surveys of prisoners have found that between one fifth and 
one third have injected drugs while in prison (2).
Injecting drug use is much more common in prisons than among the 
general population. Paradoxically, the provision of harm reduction services 
in prisons is extremely rare. In 2013 there were only eight countries 
with needle–syringe programmes in prisons: Germany, Kyrgyzstan, 
Luxembourg, the Republic of Moldova, Romania, Spain, Switzerland and 
Tajikistan (3). Opioid substitution therapy in prisons and closed settings 
was available in only 43 countries (4).
The United Nations High Commissioner for Human Rights has stressed 
that health services for prisoners must include harm reduction (5). UNODC 
recommends a comprehensive package of 15 services to respond to HIV 
within closed settings:
1. Information, education and communication.
2. Condom programmes.
3. Prevention of sexual violence.
4. Drug dependence treatment, including opioid substitution therapy.
5. Needle–syringe programmes.
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6. Prevention of transmission through medical or dental services.
7. Prevention of transmission through tattooing, piercing and other 
forms of skin penetration.
8. Post-exposure prophylaxis.
9. HIV testing and counselling.
10. HIV treatment, care and support.
11. Prevention, diagnosis and treatment of tuberculosis.
12. Prevention of mother-to-child transmission of HIV.
13. Prevention and treatment of sexually transmitted infections.
14. Vaccination, diagnosis and treatment of viral hepatitis.
15. Protecting staff from occupational hazards.
Many prison systems have expressed concerns that needle–syringe 
distribution could increase injecting drug use within prisons and that 
the presence of syringes and needles may create a more dangerous 
environment for staff and prisoners (3). Evaluations of needle–syringe 
distribution within European prisons have determined that these 
fears are unfounded. Programmes have successfully reduced needle 
sharing, syringes were not misused, disposal of used syringes was 
uncomplicated and neither drug use nor injecting drug use increased 
(6). Sharing of injecting equipment ceased after the implementation of 
most programmes, no new cases of HIV were found, and hepatitis C virus 
infections were greatly reduced (7).
Providing opioid substitution therapy during incarceration significantly 
reduces heroin use, injecting and syringe sharing within prison, 
encourages continuation of treatment after release, reduces risky 
behaviour and minimizes the risk of overdose (8). In a study of 
approaches to problem drug use and drug dependence within at least 
12 countries, the United Kingdom Home Office found that prison-based 
drug dependence treatment programmes reduce the chances of a 
prisoner committing another crime following release (9). A review of the 
programmes in 15 European countries found variations in the quality and 
coverage of treatment, generally lower standards of care than outside 
of prisons, and a host of remaining challenges. Substitution therapy was 
nevertheless found to be an efficient harm reduction measure, positively 
associated with a reduction of overdoses both within prisons and after 
release, improved health care and better management of people 
dependent on opioids (10).
An evaluation of opioid substitution therapy in prisons in Kyrgyzstan found 
that prisoners who remained on treatment for more than three months 
showed improvements in health and quality of life; they also experienced 
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a marked reduction in injecting risk behaviour and heroin use (11). In the 
Islamic Republic of Iran, methadone maintenance therapy within prisons 
has been linked to lower narcotic drug use and reductions in HIV-related 
risk behaviour (12). Malaysia established a pilot methadone programme 
in two prisons in 2008 and 2009 that links prisoners to community-
based treatment after release; among the first cohort of 57 patients who 
remained on treatment up until their release, nearly half were still on 
treatment 12 months later (13). The failure of many prison systems to 
adopt harm reduction programmes has left prisoners at extremely high 
risk of HIV and other infectious diseases. The prevalence of HIV, hepatitis 
and tuberculosis in prisons is typically 2–10 times as high as in the general 
population, and in exceptional cases it is up to 50 times higher (14).
PREVENTING SEXUAL TRANSMISSION OF HIV IN PRISONS
As well as the sharing of needles during injecting drug use, unprotected 
sex among men facilitates the spread of HIV within prisons. The 
prevalence of sexual activities within prisons has been difficult to measure, 
as prisoners may not admit to engaging in same-sex sexual activity for 
a range of reasons. Studies undertaken in a large number of countries 
confirm that consensual and forced sex does occur in prisons. Prevalence 
estimates vary from 1–2% to 4–10% or even higher (15). Opponents of 
condom provision have argued that access to condoms could encourage 
both consensual sex and rape, but a survey of more than 2000 prisoners 
in Australia found no evidence of this (16). No prison system allowing 
condoms has reversed its policy, and none has reported security problems 
or any other major negative consequences (17).
Prison systems that provide condoms and lubricant to prisoners include 
most systems in western Europe, Canada and Australia, some prisons in 
the United States, parts of eastern Europe and central Asia, Brazil, South 
Africa, the Islamic Republic of Iran and Indonesia (18). Availability of 
condoms in prisons globally remains low, however (4). A 2009 study by 
the AIDS and Rights Alliance of Southern Africa found that where same-
sex conduct was criminalized, only one country in the region distributed 
condoms to prisoners (19).
COMPULSORY HIV TESTING AND SEGREGATION OF 
PRISONERS LIVING WITH HIV
Compulsory HIV testing of prisoners and segregation of prisoners living 
with HIV persists in some countries despite evidence showing these 
practices do not achieve superior management of HIV within prisons (17). 
WHO and UNAIDS have stressed that compulsory testing of prisoners for 
HIV is unethical and ineffective and should be prohibited (20).
Voluntary HIV testing and counselling of prisoners is recommended as a 
prevention component for people who engage in risky behaviour and as a 
gateway to antiretroviral therapy, care and support. Linkage of HIV testing 
and counselling with care and treatment is essential to encouraging 
prisoners to participate in voluntary HIV testing and counselling 
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programmes (17). The few data available on antiretroviral therapy among 
prisoners suggest that coverage is low (21)—an assumption reinforced 
by individual studies and reports of prisoners struggling to access HIV 
prevention, testing and treatment services in India (22, 23), Namibia (24), 
the Russian Federation (25) and Uganda (26).
THE REPUBLIC OF MOLDOVA: A COMPREHENSIVE 
APPROACH
The Republic of Moldova is one of only a few countries that provide 
nearly all 15 services in the UNODC-recommended comprehensive 
package. Condoms, HIV counselling and testing and antiretroviral therapy 
are available in 17 prisons in the Republic of Moldova. Needle, syringe 
and condom distribution programmes were initiated in 1999, and in 
2014 the average number distributed annually reached 90 000 syringes 
and 35 000 condoms. Tuberculosis treatment has been provided since 
2001, and opioid substitution therapy was launched in 2005 (27). The 
Moldovan prison-based syringe programme is largely run by prisoners, 
which enables prisoners to avail themselves of the service without having 
to reveal their drug use to prison staff (28). Coverage of antiretroviral 
therapy in Moldovan prisons increased from 2% in 2005 to 62% in 2013; 
deaths among people living with HIV in prisons fell by nearly two-thirds, 
from 23% in 2007 to 9% in 2013. The prevalence of hepatitis C decreased 
from 21% in 2007 to 4.6% in 2015, and incidence of tuberculosis declined 
fourfold, from 550 cases in 2006 to 127 cases in 2013 (29).
NALOXONE FOR NEWLY RELEASED PRISONERS
Prisoners with a history of drug use are at high risk of drug overdose 
and death in the weeks after their release. This is due to many factors, 
including decreased tolerance after a period of relative abstinence during 
imprisonment and the concurrent use of opioids with additional illicit 
drugs (30). Provision of naloxone kits upon release can reduce overdose 
deaths among ex-prisoners. In Scotland, United Kingdom, brief training 
of prisoners and the provision of naloxone kits have been associated with 
a 36% reduction in the proportion of opioid-related deaths in the four 
weeks following release from prison (31).
Globally the provision of naloxone to prisoners upon release is rare, 
especially outside western Europe. In the United States, the expansion of 
naloxone provision to counteract a rising trend in drug overdose deaths 
is leaving prisoners behind. Only a few prisons provide naloxone kits 
to at-risk prisoners upon release (32). In the state of Rhode Island, drug 
overdose is the leading cause of accidental death among adults (33), and 
in early 2014 the majority of people who died of a drug overdose had 
spent time in prison (32). In 2007 a pilot naloxone programme began 
providing overdose prevention training to prisoners before release, and in 
2011 naloxone kits began being provided after release (34).
HEPATITIS C VIRUS AND TUBERCULOSIS IN PRISONS
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The prevalence of hepatitis C virus ranges from 3.1% to 38% among 
prisoners and has been linked to sharing injecting equipment, tattooing 
and unprotected sexual intercourse (35). A high prevalence of HIV, 
overcrowding, poor ventilation, drug use and previous unhealthy lifestyles 
have been identified as contributors to the spread of tuberculosis within 
prisons (36). One study estimated that growth in the prison populations of 
26 eastern European and central Asian countries accounted for a 20.5% 
increase in tuberculosis incidence from 1991 to 2002, or nearly four fifths 
of the average total increase in tuberculosis incidence in the countries 
studied (36). A systematic review found that improving tuberculosis 
control in prisons would significantly reduce a country’s overall 
tuberculosis disease burden (37).
Despite the clear need, coverage of these essential health services 
remains low within the prison systems of many countries. Insufficient 
budgets are often cited as a barrier to providing appropriate health care 
to prisoners. Researchers estimated that providing hepatitis C treatment 
to all the prisoners in need in Rhode Island would cost nearly twice 
the entire annual health-care budget of the state’s correctional system 
(38). The longer-term cost to the United States Government and the 
community of failing to provide that treatment is rarely assessed, however. 
Giving higher priority to prisoners’ health is clearly required in many 
countries.
Courts around the world have described failure to provide people 
in prisons and other closed settings with the necessary medical care 
as inhumane and degrading treatment. The United Nations Special 
Rapporteur on the Right to Health has stressed that if harm reduction 
programmes and evidence-based treatments are made available to the 
general public but not to people in detention, it is a violation of the right 
to health (21). In South Africa, a landmark Constitutional Court ruling in 
2012 found the South African prison system responsible for a prisoner’s 
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versus after (2011–13) comparison. Addiction. doi: 10.1111/add.13265.
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tuberculosis infection (39). Since the ruling, there has been significant 
investment in the prison system’s capacity to diagnose and treat 
tuberculosis, including systematic symptom screening coupled with the 
use of on-site Xpert MTB/RIF tests for people who are symptomatic. The 
country’s TB/HIV Care Association is supporting 95 correctional facilities 
across the country. In Pollsmoor prison, where Nelson Mandela was once 
held, close to 90 000 prisoners have been screened for tuberculosis since 
2013 and 915 were on treatment in 2015 (40). An early evaluation of the 
initiative found the scale-up of services effective and comparable in cost 
to other screening programmes (41).
Continuity of care is critical for people entering and leaving prisons and 
other closed settings, as interrupting treatments for HIV, tuberculosis or 
drug dependence has serious health consequences for the patients and 
the communities they are returning to. Multiple studies have shown that 
prisoners respond well to antiretroviral therapy and can achieve levels 
of adherence that are as high as or higher than those found in people in 
the community, but the gains in health status made in prison may be lost 
unless careful efforts are undertaken to link released prisoners to care 
within their communities (42). The spread of HIV and other infectious 
diseases in prisons is thus a wider public health issue (43).
Both linkage to HIV care after testing positive for HIV and retention in 
care after initiation of antiretroviral therapy are lower after release from 
prison in the United States, where less than 20% of prisons and jails 
provide services for the transition of released prisoners to community 
care as per national guidelines (44). To improve prison conditions and 
ensure prisoners receive the health care they need, UNODC and WHO 
have called for prison health services to be placed under the authority 
of ministries of health (45). France, Italy, Norway, the United Kingdom 
and parts of Switzerland and Spain are among the countries that have 
transferred responsibility of prison health to their health ministries (45).
ACTION AREAS
 • Make UNODC’s comprehensive package of 15 HIV services available to 
all prisoners.
 • Ensure the availability of essential health services, including tuberculosis 
and hepatitis C virus screening and treatment, to all prisoners.
 • End compulsory HIV testing and the segregation of prisoners living with 
HIV.
 • Ensure that naloxone kits are provided to prisoners with a history of 
drug use upon their release.
 • Ensure continuity of care for individuals entering and leaving prisons 
and other closed settings.
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“A criminal record for a young person for a minor drug offence can 
be a far greater threat to their well-being than occasional drug use.”
Former United Nations Secretary-General Kofi Annan, 19 May 2015, speaking at 
the meeting “Strengthening a public health approach when addressing the world 
drug problem”
The 1988 United Nations Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances called on countries to include the 
possession of narcotic drugs and psychotropic substances for personal 
consumption as a criminal offence under their domestic law. International 
agreement to this provision coincided with a 30-year global increase in the 
criminalization of drug possession and use (1, 2). In 2011 offences related to 
drug possession comprised 83% of total global drug-related offences (2).
More aggressive policing and sanctioning have had little or no impact on 
the number of people using drugs. Country data collected by UNODC 
show that the percentage of people who use illicit drugs has remained 
stable, fluctuating between 4.6% and 5.2% of adults, since at least 2006 
(3). Unsurprisingly, research has determined that the imprisonment of 
drug offenders is not cost effective. In the United States, the states of 
Washington, Oregon and New York separately calculated that they 
received, respectively, only US$ 0.37, US$ 0.35 and US$ 0.29 in public 
safety benefits for every dollar invested in the incarceration of drug 
offenders, which means the costs were roughly three times more than the 
benefits (4, 5).
REFORM AND EMPOWERMENT
Global trends in (a) the estimated number of drug usersa and (b) prevalence of useb, 2006–2013
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Any benefits from the criminalization of drug use and the possession 
and sale of small amounts of drugs appear to be far outweighed by the 
increase in harms these policies create. Criminalization has been shown to 
perpetuate risky forms of drug use, to increase the risk of illness (including 
from HIV infection) among people who use drugs, to discourage 
people who use drugs from seeking health care, and to reinforce the 
marginalization by society of people who use drugs (6).
Criminalization has specific effects on women and their families. Globally, 
women are imprisoned for drug-related offences more than for any other 
crime (7). In some countries in the Americas, Europe and central Asia, 
40–70% of women in prison are incarcerated for low-level, non-violent, 
drug-related offences (8), such as selling small quantities of drugs or 
serving as mules to carry drugs from one country to another (9). Many of 
these women are young, illiterate, impoverished single mothers who are 
struggling to take care of their children and other family members (9). In 
some countries, drug-related convictions can result in a woman losing 
custody of her children and forced or coerced sterilization or abortion (7). 
Children left behind are vulnerable to marginalization and may engage in 
criminal activity or problem drug use themselves as they struggle to cope 
with living on the streets, in institutions, in foster care or with relatives (10).
PEOPLE-FRIENDLY POLICING STRATEGIES
The incorporation of human rights safeguards within drug control laws 
and drug-related law enforcement is critical to the prevention of human 
rights abuses. As the human toll of punitive approaches mounts alongside 
persistent drug trafficking, drug use and drug-related crime, an increasing 
number of law enforcement agencies are buying into alternative, public 
health approaches to drug use.
In the United States city of Seattle, a coalition of law enforcement 
agencies, public officials and community groups collaborated to establish 
the Law Enforcement Assisted Diversion (LEAD) programme in 2011. 
Under this programme, police who would normally arrest and prosecute 
people caught in possession of drugs instead redirect them to community-
based services, including drug dependence treatment. This diversion is 
done before an individual is officially booked for an offence, which avoids 
the costs and time entailed in booking, charging and requiring court 
appearances of an individual (11). A 2015 evaluation of the programme 
found a significantly lower level of criminal behaviour among beneficiaries 
of the programme compared with a control group. LEAD beneficiaries 
were 60% less likely to be arrested within their first six months in the 
programme, were 58% less likely to be arrested at all, and were 39% less 
likely to be charged with a felony crime (12). The costs of the programme 
(US$ 899 per person per month at start-up, and US$ 532 per person 
per month after several years of operation) were found to be similar to 
supportive programmes for homeless people, and there were substantial 
reductions in criminal justice and legal costs for LEAD beneficiaries 
compared with the control group (13).
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The success of LEAD begs the question of whether criminalization of the 
possession and use of small amounts of narcotic drugs is an effective 
approach within drug control systems.
DEPENALIZATION AND DECRIMINALIZATION
A large body of evidence shows that alternatives to incarceration such as 
community-based drug dependence treatment are more cost effective at 
reducing health, social and economic harms of drug use (14). The United 
Nations Special Rapporteur on the Right to Health concluded in 2010 that 
decriminalization or depenalization of possession and use of drugs is an 
important step towards fulfilling the right to health, an analysis echoed by 
the United Nations High Commissioner for Human Rights in a 2015 study 
on the impact of the world drug problem on the enjoyment of human 
rights (7).
Several countries are moving away from criminalization of drug use. 
Armenia, Belgium, Chile, the Czech Republic, Estonia, Mexico and 
Portugal are among the countries that have adopted some form of 
decriminalization policy since 2000 (15). In the Netherlands and Germany, 
possession for personal use is illegal, but guidelines are established 
for police and prosecutors to avoid imposing punishment (15). In total, 
depending on the definition used, between 25 and 30 countries had 
decriminalized or depenalized drug possession and use by 2012 (15).
The Czech Republic’s decriminalization of the use and possession of small 
quantities of drugs combined with relatively high coverage of needle–
syringe programmes and opioid substitution therapy have been credited 
with the country’s remarkably low rates of HIV among people who inject 
drugs, especially when compared with other countries in central and 
eastern Europe (16). Nearly 90% of people who inject drugs in the Czech 
Republic report using sterile injecting equipment the last time they 
injected, and HIV prevalence among people who inject drugs in 2012 was 
estimated to be 0.1% (17).
Among the best documented policy changes is Portugal’s. In 2000, 
Portugal passed a new drug law that downgraded purchase, possession 
and consumption of small amounts of narcotic drugs from criminal to 
administrative offences. Under the law an individual can possess a 10-day 
supply of drugs before facing criminal charges as a drug dealer. The law 
also put in place a wide range of drug use prevention measures focused on 
high-risk groups and areas, and systematic application of harm reduction 
measures, including needle–syringe distribution and drug dependence 
treatment. Reintegration teams assist people undergoing drug treatment to 
return to education or employment and reintegrate into their communities, 
and actively work to dispel stigma and discrimination (6).
The 10 years after Portugal’s law was enacted saw a decline in the rate 
of crimes related to drug consumption, especially petty thefts (18). 
Levels of drug use in Portugal have fluctuated since the policy change, 
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which has been the subject of intense debate between proponents and 
opponents of the policy. Contrary to the predictions of opponents of 
decriminalization, the policy change has not led to a dramatic increase in 
drug use, and drug use levels remain below the European average (19). 
There is evidence of reductions in problematic drug use, drug-related 
harms and criminal justice overcrowding (20), and the number of people 
entering drug dependence treatment programmes in Portugal increased 
from just over 5000 in 2008 to 40 000 in 2010 (18). The experience of 
Portugal reinforces multi-country analyses that have found little or no 
relationship between the strictness of national drug policies and illicit drug 
use (21, 22).
The public health benefits of Portugal’s drug policy are clear. Since 2000 
there has been a steady decrease in the number of people who inject 
drugs newly infected with HIV, and a huge decrease in the percentage of 
people who inject drugs among new HIV infections (18). In 2013 a total 
of 78 new HIV cases were related to drug use, compared to 1430 in 2010 
(23). A similar downward trend has been observed for hepatitis C and 
hepatitis B among people attending drug treatment centres, despite an 
increase in the number of people seeking treatment (19).
A review of countries that have decriminalized or relaxed criminal 
penalties for possession and use of small quantities of drugs found that 
these countries generally were able to direct more people who are drug 
dependent into dependence treatment; they also experienced a reduction 
in criminal justice costs. The review concluded that decriminalization 
coupled with investment in harm reduction can have a positive impact on 
individual drug users and society as a whole (15).
Numbers of people newly diagnosed with HIV in Portugal since the decriminalization of drug use, 2000–2013
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The growing body of evidence has fuelled a rising chorus for change. 
WHO has called on countries to work towards policies and laws that 
decriminalize injection and other uses of drugs to reduce incarceration 
and improve coverage of harm reduction services (24). The International 
Narcotics Control Board has increasingly stressed a need for a 
balanced approach to drug control “in which prevention, treatment and 
rehabilitation take a leading role”. A joint statement of experts following 
a UNODC scientific consultation in 2014 declared “an urgent need to 
realign harm reduction and law enforcement approaches to support 
prevention and treatment of HIV and hepatitis C among people who inject 
drugs”, and the Johns Hopkins–Lancet Commission on Drug Policy and 
Health has specifically called for the decriminalization of use, possession 
and petty sale of drugs, and the strengthening of health and social-sector 
alternatives to criminal sanctions (25).
The outgoing President of the International Narcotics Control Board, 
Lochan Naidoo, told the 58th session of the Commission on Narcotic 
Drugs in 2015 that “nothing in the [drug control] conventions requires 
states to incarcerate drug users” (26). During the same session, the 
Commission passed a resolution that called on public health and justice 
authorities to collaborate in the pursuit of “alternative measures to 
conviction or punishment for appropriate drug-related offences of a minor 
nature” (27). A few months later, the new President of the International 
Narcotics Control Board, Werner Sipp, described Portugal’s drug policy 
as “a model of best practices” that puts health and welfare at the centre 
of “a balanced, comprehensive and integrated approach, based on the 
principle of proportionality and the respect for human rights” (28).
COMMUNITY EMPOWERMENT
“We are people from around the world who use drugs. We are people 
who have been marginalized and discriminated against; we have 
been killed, harmed unnecessarily, put in jail, depicted as evil, and 
stereotyped as dangerous and disposable. Now it is time to raise 
our voices as citizens, establish our rights and reclaim the right to 
be our own spokespersons striving for self-representation and self-
empowerment...”
Vancouver Declaration–The International Activists who use Drugs, 30 April 
2006 | Vancouver, Canada
Civil society’s unique role within the global HIV response for more than 
three decades has demonstrated the breadth of community contributions 
to efforts to improve health care and social justice for marginalized 
populations. A review by UNAIDS and the Stop AIDS Alliance in 2015 
identified four components of community responses to HIV: advocacy, 
campaigning and participation in accountability; service delivery; research 
and evidence generation; and community financing. These components 
are also relevant to the participation of people who use drugs within 
efforts to develop more effective approaches to drug use.
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Community engagement in harm reduction dates back to at least the mid-
1970s, when former users of heroin in Chicago were hired to reach hidden 
populations of people who inject drugs to encourage them to enter 
methadone maintenance therapy (29). Peer support is based on the belief 
that people who have faced, endured and overcome adversity can offer 
useful support, encouragement, hope and mentorship to other people 
facing similar situations (30). As outreach models spread, the power of 
peers was increasingly understood. By the late 1990s, enlisting active 
users of drugs was found to be more effective at providing entire networks 
of people who inject drugs with sterile injecting equipment, rather than 
only a few individuals (29). In 2004, WHO compiled the overwhelming 
evidence of the effectiveness of peer outreach in the prevention of HIV 
among people who inject drugs to assist countries to establish more 
effective HIV programmes (29). Peer support has also been shown to 
improve drug dependence treatment (31), and UNODC recommends 
the engagement of people who use drugs within community-based drug 
dependence treatment programmes (32).
In India, the Hridaya community-based harm reduction project has built 
partnerships between existing government health services and civil society 
organizations of the people who inject drugs within the states of Bihar, 
Haryana, Uttarakh and Manipur. The project provides a comprehensive 
range of harm reduction, health and social services to people who inject 
drugs and their sexual partners. Peers provide psychosocial support and 
enhance referral to external services. Of particular note is the engagement 
of female outreach workers to work with the sexual partners and families 
of people who inject drugs, and to recruit new clients into regular services. 
The Hridaya project has also facilitated the participation of people who 
use drugs in forums that influence state-level decision-making (33).
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The experiences of countries with HIV epidemics predominantly among 
people who inject drugs were used to develop a harm reduction 
programme in Kenya, where a high-level HIV epidemic among the general 
population is in decline while HIV prevalence among people who inject 
drugs is approximately 18%. Many people who use drugs in Kenya avoid 
health services out of fear of discrimination, stigmatization and arrest. To 
address this, the Community Action on Harm Reduction project and the 
Kenyan AIDS NGOs Consortium used a peer outreach model to provide 
sterile injecting equipment to people who inject drugs and to link these 
people to HIV testing and treatment, sexual and reproductive health 
services, counselling, legal support, housing and income-generating 
activities. Over five years of implementation in Nairobi and four coastal 
towns (Mombasa, Malindi, Kilifi and Ukunda), the project provided services 
to almost 10 000 people who inject drugs (34). At the start of the project 
in 2011, 51.6% of the surveyed people who inject drugs had used a sterile 
syringe the last time they injected. In 2015, a follow-up survey found that 
90% reported using sterile injecting equipment at last injection, greatly 
reducing their risk of HIV transmission (34).
CIVIL SOCIETY ADVOCACY FOR CHANGE
Over the past 25 years, small groups of peer outreach workers have 
bound together into communities with shared experiences, which have 
in turn established national organizations and international networks of 
people who use drugs. These civil society organizations have forged 
identities, self-respect and empowerment not only to provide support to 
community members but also to raise awareness and provoke change. 
Their experiences and insights must be recognized as critical contributions 
to the evolution of national drug laws and policies and the debate within 
the UNGASS on the World Drug Problem.
Civil society advocacy for sufficient, strategic and sustainable investments 
in harm reduction as HIV prevention in the region of eastern Europe 
and central Asia is being strengthened by the Eurasian Harm Reduction 
Network and the Global Fund (35). During its first year of implementation, 
the project conducted a financial analysis of harm reduction service costs 
and a community-led assessment of service quality in Belarus, Georgia, 
Kazakhstan, Lithuania, the Republic of Moldova and Tajikistan. The harm 
reduction funding and coverage gaps revealed by the assessments suggest 
that the region is far from achieving sustainable control of the spread of 
HIV. The Eurasian Harm Reduction Network and its partners have called 
on governments in the region to provide greater sustained state funding 
for harm reduction and to put in place policy reforms that will facilitate 
service delivery, such as the enactment of legislation to ensure possession of 
injecting equipment is not used by the criminal justice system as evidence 
of illegal drug use, and the recognition of opioid substitution therapy as a 
legitimate drug dependence treatment (36).
55
The International Network of People Who Use Drugs is one of several 
peer-based organizations that have engaged in the Civil Society Task 
Force and Civil Society Hearings for the UNGASS on the World Drug 
Problem. The formal submission of the International Network of People 
Who Use Drugs to the Task Force calls on United Nations Member States 
to recognize people who use drugs as experts on drug use who must be 
meaningfully engaged in the debate on the future of global drug policy 
(37). The Eurasian Harm Reduction Network and the Eurasian Network of 
People Who Use Drugs have urged governments in central and eastern 
Europe and central Asia to expand harm reduction in the region far 
beyond the small pilot schemes that are mostly funded by international 
donors (38).
The proponents of peer support describe the deep bonds that are 
established by mutual experience, and how the strength of a peer 
community can be leveraged to question previously held concepts and 
experiment with new behaviour (39). The shared experiences of countries 
struggling to control the global drug trade could be similarly leveraged 
to listen carefully to the advice of people who use drugs and to expand 
the use of alternative policy options that place people at the centre of a 
rights-based public health approach to drug use.
ACTION AREAS
 • Use people-friendly policing strategies to reduce violence and the 
incarceration of people who use drugs.
 • Adapt and reform laws to ensure that people who use drugs do not 
face punitive sanctions for the use of drugs or possession of drugs for 
personal use.
 • Empower and finance communities of people who use drugs to 
advocate for their rights and participate in research and the delivery of 
services.
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A struggle between an increasingly violent network of organized criminals 
and an increasingly militarized coalition of anti-narcotics police has 
dominated a half-century of efforts to control the production, sale and use 
of narcotic drugs and psychotropic substances. Caught in the crossfire 
are 246 million people who use drugs. They have been marginalized, 
denied health and social services, severely punished, forced to undergo 
unwanted medical tests and treatment, and exposed to HIV and a host of 
other harms. Hundreds of millions of additional people have been denied 
access to the medicines they need for pain relief.
The UNGASS on the World Drug Problem is an opportunity to refocus 
the international drug control system on its original goal—the health 
and well-being of humankind. The International Narcotics Control 
Board, United Nations System agencies and a growing body of scientific 
research have called for the scale-up of harm reduction within a balanced 
approach to drug control. Within this approach, UNAIDS has put forth five 
policy recommendations and 10 operational recommendations that can 
accelerate efforts to establish a people-centred public health and human 
rights-based approach to drug use.
FIVE POLICY RECOMMENDATIONS
1. Recognize that the overarching purpose of drug control is first and 
foremost to ensure the health, well-being and security of individuals, 
while respecting their agency and human rights at all times.
2. Ensure accountability for the delivery of health services for people 
who use drugs by including public health and human rights pillars in 
the framework of the UNGASS outcome document that incorporate 
clear objectives for reducing new HIV infections and protect and 
promote the rights of people who inject drugs.
3. Commit to fully implement harm reduction and HIV services, as 
outlined in the World Health Organization’s consolidated guidelines 
on HIV prevention, diagnosis, treatment and care for key populations.
4. Commit to treating people who use drugs with support and care, 
rather than punishment. UNAIDS believes that this objective can be 
achieved only by implementing alternatives to criminalization, such 
as decriminalization and stopping incarceration of people for the 
consumption and possession of drugs for personal use. 
5. Ensure integration of HIV services with other health and social 
protection services for people who use drugs.
CONCLUSION
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TEN OPERATIONAL RECOMMENDATIONS
1. Ensure that all people who inject drugs, including people in prisons 
and other closed settings, have access to harm reduction services to 
prevent HIV infection, including needle–syringe programmes, opioid 
substitution therapy and antiretroviral therapy.
2. Ensure that all people who inject drugs and are living with HIV have 
access to life-saving antiretroviral therapy and other health services 
to manage tuberculosis, viral hepatitis and sexually transmitted 
infections. In addition, ensure adequate availability and access to 
opioids for medical use to reduce pain and suffering.
3. Ensure that all people who use drugs have access to non-coercive 
and evidence-informed drug dependence treatment consistent with 
international human rights standards and the Principles of Drug 
Dependence Treatment articulated by the United Nations Office 
on Drugs and Crime and the World Health Organization. All forms 
of compulsory drug and HIV testing and drug treatment should be 
replaced with voluntary schemes. The use of compulsory detention 
centres for people who use drugs should cease, and existing centres 
should be closed.
4. Adapt and reform laws to ensure that people who use drugs do not 
face punitive sanctions for the use of drugs or possession of drugs for 
personal use. Countries should consider taking a range of measures, 
including alternatives to criminalization, incarceration, penalization 
and other penalties based solely on drug use or possession of drugs 
for personal use. These measures include decriminalization, steps 
to reduce incarceration, removal of administrative penalties and 
depenalization.
5. Ensure that the human rights of people who use drugs are not 
violated, by providing access to justice (including through legal 
services), prevention, treatment and other social services. Adopt 
smart policing measures to encourage people to access public health 
services.
6. Recognize that stigma and discrimination impede access to HIV 
prevention, treatment and other health and development services, 
and ensure that all people who use drugs are not discriminated 
against while accessing health, legal, education, employment and 
other social protection services.
7. Recognize that incarcerating people in prisons increases their risk of 
drug use, HIV infection and other health conditions, and take steps to 
ensure that harm reduction and other health services are available in 
prisons in parallel with efforts to reduce the number of people being 
incarcerated for non-violent drug offences.
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8. Ensure the widespread availability of naloxone among health 
workers, first responders, prison staff, enforcement officials and family 
members as a life-saving public health measure to enable timely and 
effective prevention of deaths from opioid overdose among people 
who use drugs.
9. Support and empower community and civil society organizations, 
including organizations and networks of people who use drugs, in the 
design and delivery of HIV, health and social protection services.
10. Undertake a rebalancing of investments in drug control to ensure 
that the resources needed for public health services are fully funded, 
including harm reduction for HIV infection, antiretroviral therapy, drug 
dependence treatment and treatment for hepatitis, tuberculosis and 
other health conditions.
The preamble of the United Nations Charter places the international 
community’s collective faith in fundamental human rights, in the dignity 
and worth of the human person, and in the equal rights of men and 
women and of nations large and small. It calls on Member States to ensure 
justice, to promote social progress and better standards of life, and to be 
tolerant of their neighbours. Establishing a people-centred public health 
and human rights-based approach to drug use will ensure that these core 
concepts established during the founding of the United Nations also 
apply to people who use drugs.
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COUNTRY PROFILES
Thirty-two countries are 
home to approximately three 
quarters of the world’s people 
who inject drugs.
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AFGHANISTAN
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
The National Harm Reduction Policy guides the provision of needles and syringes, condoms and opioid 
substitution therapy.
POLICING
There are no criminal penalties or other sanctions for the possession of needle/syringes and other drug 
paraphernalia.
6000
[4000–12 000]
PEOPLE LIVING  
WITH HIV
4%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
31%
OF PEOPLE WHO INJECT DRUGS LIVING 
WITH HIV ARE COINFECTED WITH 
HEPATITIS C VIRUS
20%
ARE WOMEN 
AND GIRLS
21 000 
[19 000–23 000] 
PEOPLE WHO INJECT DRUGS
Sources: National drug use survey: Aghanistan. Vienna: United Nations Office on Drugs and Crime; 2009 
National programme data. 
Integrated biological and behavioural survey, Afghanistan, 2012.
Source: UNAIDS country office report, 2016.
+
+
61
Sources: NACP, National programme data, 2015. 
Integrated biological and behavioural survey, Afghanistan, 2012. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
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13%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
AUSTRALIA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
Harm reduction features strongly in the national hepatitis C strategy and the national drug strategy.
POLICING
There are no criminal penalties or other sanctions for the possession of needles, syringes or other drug 
paraphernalia.
CRIMINALIZATION
Possession of small quantities of drugs other than cannabis for personal use is a criminal offence 
punishable by a large fine and imprisonment (sentences vary by state).
OVERDOSE TREATMENT
Naloxone is available without prescription to people likely to witness an overdose.
50 000 
PEOPLE WHO 
INJECT DRUGS
+
+
+
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31 000
[24 000–37 000]
PEOPLE LIVING  
WITH HIV
2.1%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: Harm reduction, Australian Government Department of Health, 2008 (http://www.health.gov.au/internet/publications/publishing.
nsf/Content/phd-hepc-manual-toc~phd-hepc-manual-ch3~phd-hepc-manual-ch3-4). Drug law in Australia, Australian Drug Foundation, 
2015 (http://www.druginfo.adf.org.au/topics/drug-law-in-australia#illegal). Final decisions and reasons for decisions by a delegate of the 
Secretary to the Department of Health, Therapeutic Goods Administration, 2015.
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Dore, G. & Sasadeusz, J. (Eds) (2006). Co-infection: HIV & Viral hepatitis a guide for clinical management. ASHM. 
Australian Institute of Health and Welfare 2014. National Drug Strategy Household Survey detailed report 2013. Drug statistics series no. 
28. Cat. no. PHE 183. Canberra: AIHW.
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HARM REDUCTION
50.1%
tested for HIV and 
received the result 
within the last  
12 months
48 393
people enrolled in opioid 
substitution therapy
203
syringes distributed per person 
who inject drugs per year
1
safe injecting  
facility
SERVICES AVAILABLE IN PRISONS
31.9%
used a condom  
during last risky sex
78.5%
used sterile  
equiptment at 
last injection
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
The global state of harm reduction 2014. London: Harm Reduction International; 2014
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
Australian Institute of Health and Welfare, Australian Government. National opioid
pharmacotherapy statistics, 2014.
Sources: Australian Institute of Health and Welfare, Australian Government. The health of Australia’s prisoners, 2012. 
The global state of harm reduction 2014. London: Harm Reduction International; 2014
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf). 
   HIV TESTING
   ANTIRETROVIRAL THERAPY
 
   CONDOMS
   NEEDLES AND SYRINGES
   OPIOID SUBSTITUTION THERAPY
64
AZERBAIJAN
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
INSUFFICIENT ENABLING POLICY
The country’s policy framework does not have explicit supportive reference to harm reduction, but 
needle and syringe distribution and opioid substitution therapy are available.
DOMESTIC INVESTMENT
The financing of harm reduction in this lower-middle-income country is highly reliant on external funding, 
accounting for 96% of all funding in 2014.
71 000 
PEOPLE WHO 
INJECT DRUGS
–
–
8000
[6000–12 000]
PEOPLE LIVING  
WITH HIV
9.5%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: The global state of harm reduction 2014, London, Harm Reduction International, 2014 (http://www.ihra.net/files/2015/02/16/
GSHR2014.pdf); Global AIDS response progress report, Government of Azerbaijan, 2014.
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
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Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
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BELARUS
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
REGISTRATION OF PEOPLE WHO USE DRUGS
The Narcological Service of the Ministry of Health routinely registers known people who use or who are 
dependent on drugs. Since 2015 new registrations are routinely reported by health-care facilities to law 
enforcement agencies.
CRIMINALIZATION
A 2015 Presidential decree toughens criminal penalties for the production, transport and sale of illegal 
drugs and introduces administrative sanctions for drug use.
DOMESTIC INVESTMENT
The financing of harm reduction is being steadily transitioned from the Global Fund to Fight AIDS, 
Tuberculosis and Malaria to domestic sources. Opioid substitution therapy is almost completely funded 
by the state budget.
36%
ARE WOMEN 
AND GIRLS
67 000 
PEOPLE WHO 
INJECT DRUGS
Source: Integrated biological and behavioural survey, Belarus, 2015.
+
–
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25.1%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
90.6%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
29 000
[24 000–36 000]
PEOPLE LIVING  
WITH HIV
Source: UNAIDS country office report, 2016. EMCDDA, Country overview: Belarus.
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Sources: Integrated biological and behavioural survey, Belarus, 2015. 
Ministry of Health report, 2015.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
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CANADA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
A national harm reduction framework developed by the Canadian Government guides action to reduce the 
harms associated with alcohol and other drugs and substances from the national to the community level.
OVERDOSE TREATMENT
Naloxone was delisted by national authorities in March 2016 to make it more easily available to people 
likely to witness an opioid overdose; it is up to individual provinces to make naloxone available without a 
prescription.
REACHING THE MOST MARGINALIZED
Drug consumption rooms and heroin-assisted drug dependence treatment are available in cities with 
large populations of people who inject drugs.
+
+
76 000
[63 000–88 000]
PEOPLE LIVING  
WITH HIV
12.9%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
+
Sources: National framework for action to reduce the harms associated with alcohol and other drugs and substances in Canada, Drug Strategy 
and Controlled Substances Programme and the Canadian Centre on Substance Abuse, 2005. Notice: Prescription Drug List (PDL): naloxone, 
Health Canada, 2016 (http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl-ldo-noa-ad-naloxone-eng.php). Insight into Insite, Vancouver, 
Urban Health Research Initiative, 2010 (http://www.ohrdp.ca/wp-content/uploads/pdf/insite.pdf). Strang J, Groshkova T, Metrebian N, New 
heroin-assisted treatment: recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond, Luxembourg, 
European Monitoring Centre for Drugs and Drug Addiction, 2012.
Sources: Public Health Agency of Canada, revised estimate for 2014 estimation exercise.
90 000 
[72 000–108 000]
PEOPLE WHO 
INJECT DRUGS
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HARM REDUCTION
79.6%
tested for HIV and 
received the result 
within the last  
12 months
-
people enrolled in opioid 
substitution therapy
-
syringes distributed per person 
who inject drugs per year
2
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
35.8%
used a condom  
during last risky sex
Sources: Public Health Agency of Canada, I-Track Surveillance System, Phase 3 (2010–2012).
Public Health Agency of Canada, programme data reported to UNAIDS, 2016.
Source: Corrections Services Canada, programme data reported to UNAIDS, 2016.
94.5%
used sterile  
equiptment at 
last injection
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CHINA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
The National Health and Family Planning Commission, the Ministry of Public Security and the State Food and 
Drug Administration jointly formulated guidelines for methadone maintenance therapy that are guiding the 
expansion of one of the world’s largest opioid substitution therapy programmes.
REGISTRATION OF PEOPLE WHO USE DRUGS
Individuals dependent on heroin or other narcotic drugs are permanently registered in a government tracking 
system, even if they successfully undergo drug dependence treatment.
CRIMINALIZATION
Possession of more than 200 grams of opium, 10 grams of methamphetamines and 10 grams of heroin can 
result in up to three years in prison.
POLICING
There are no criminal penalties or other sanctions for the possession of needle/syringes and other drug 
paraphernalia.
COMPULSORY DETENTION
In 2015, 264 000 people who use drugs were newly detained in compulsory detention centres. 
1 930 000 
PEOPLE WHO 
INJECT DRUGS
Sources: HIV estimation, China, 2013.
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
+
+
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810 000
[640 000–970 000]
PEOPLE LIVING  
WITH HIV
6%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: UNAIDS country office report, 2016. Kamarulzaman A, McBrayer J, Compulsory drug detention centers in East and Southeast 
Asia, Int J Drug Policy 2015;26:S33–S37.
–
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77.8%
used sterile  
equiptment at last 
injection
40.5%
tested for HIV and 
received the result 
within the last  
12 months
184 000
people enrolled in opioid 
substitution therapy
204
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
44.8%
used a condom  
during last risky sex
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: National Center for AIDS/STD Control and Prevention, China.
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CZECH REPUBLIC
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
Harm reduction has been a core part of the national drug policy since it was first established 
in 1992.
DECRIMINALIZATION
Decriminalization of the use and possession of small quantities of drugs combined with 
relatively high coverage of needle–syringe programmes and opioid substitution therapy have 
been credited with the country’s remarkably low rates of HIV among people who inject drugs.
POLICING
There are no criminal penalties or other sanctions for the possession of needle/syringes and 
other drug paraphernalia.
42 700 
PEOPLE WHO 
INJECT DRUGS
Sources: National report: the Czech Republic 2013 drug situation. Prague: National Monitoring Centre for Drugs and Addiction; 2014 
(http://www.emcdda.europa.eu/attachements.cfm/att_239732_EN_VZ_2013_EN_final.pdf).
Treatment Demand Register and National Monitoring Centre for Drugs and Drug Addiction of the Czech Republic, 2012.
UNODC, 2013.
+
+
+
4000
[3000–5000]
PEOPLE LIVING  
WITH HIV
0.7%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: EMCDDA, Country overview: Czech Republic. Office of the Government of the Czech Republic, Annual report: the 
Czech Republic—2010 drug situation. Csete J, A balancing act: policymaking on illicit drugs in the Czech Republic, Global 
Drug Policy Program, 2012.
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Sources: Czech National Monitoring Centre for Drugs and Drug Addiction, unpublished data, 2016. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: National Monitoring Centre for Drugs and Addiction, Czech Republic, unpublished data, 2016.
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EGYPT
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
INSUFFICIENT ENABLING POLICY
Needle and syringe distribution is limited to a network of nongovernmental organizations funded by 
international assistance and opioid substitution therapy is not among the drug dependence treatment 
options approved by health authorities.
CRIMINALIZATION
People caught in possession of small amounts of drugs for personal use face heavy fines and lengthy 
incarceration.
POLICING
Possession of needle/syringes and other drug paraphernalia can be considered evidence of drug use 
and drug dealing.
93 000 
PEOPLE WHO 
INJECT DRUGS
Sources: Population size estimation, Egypt, 2015.
Integrated biological and behavioural survey, Egypt, 2010.
–
–
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9000
[6000–14 000]
PEOPLE LIVING  
WITH HIV
7%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: UNAIDS country office report, 2016.
Egypt National AIDS Programme, National HIV programme situation and gap analysis, 2015; Oraby D, Harm reduction approach in Egypt: 
the insight of injecting drug users, Harm Reduct J, 2013;10:17.
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Sources: Integrated biological and behavioural survey, Egypt, 2010.
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
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FRANCE
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
Since 2004 harm reduction policies have been incorporated in public health regulations and state 
jurisdiction. A network of 154 low-threshold agencies receive funding directly from the social security 
system for needle and syringe distribution. 
DEPENALIZATION
Use or possession of narcotic drugs is a criminal offence. Directives issues in 2008 and 2012 established 
depenalization measures, including cautions, compulsory drug awareness courses and court-ordered  
drug dependence treatment.   
MOBILE METHADONE
Two buses provide mobile methadone maintenance therapy to improve access to opioid substitution 
therapy. 
OVERDOSE PREVENTION
A nasal spray formulation of naloxone was approved in February 2015. A take-home naloxone 
programme will be launched in 2016.
145 000 
PEOPLE WHO 
INJECT DRUGS
Sources: Costes et al. Prévalence de l’usage problématique de drogues en France - estimations 2006. 2009.
Weill-Barillet L et al. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of 
geographical areas in France, ANRS-Coquelicot 2011 survey. Rev Epidemiol Sante Publique. 2016.
Supervie V, Koumavi Ekouevi D. Épidémiologie de l’infection par le VIH en France et dans le monde. Rev Prat 2014;64(8):1060-6.
Roux P. La co-infection par le virus de l’hépatite C chez les personnes infectées par le VIH : données de l’enquête ANRS-Vespa2 , BEH (Bulletin Épidémiologique 
Hebdomadaire), N°26-27, 2013.
+
+
+
+
150 000
[143 000–156 000]
PEOPLE LIVING  
WITH HIV
13%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Sources: EMCDDA. Harm reduction overview for France.
EMCDDA. Country overview: France.
François Beck, French Monitoring Centre for Drugs and Drug Addiction, personal communication, 6 April 2016. 
87%
OF PEOPLE WHO INJECT DRUGS LIVING WITH HIV 
ARE COINFECTED WITH HEPATITIS C VIRUS
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Sources: Workbook 3.4: harms and harm reduction. 2015 national report to the EMCDDA.  Paris: Observatoire Français des Drogues et 
des Toxicomanies; 2015 (http://en.ofdt.fr/BDD/publications/docs/natrep2015ENwb34.pdf).
Enquête ENA-CAARUD 2012.
Source: Workbook 5.1: prison. National report 2015 to the EMCDDA. Paris: Observatoire Français des Drogues et des Toxicomanies; 2014 
(http://en.ofdt.fr/BDD/publications/docs/natrep2015ENwb51.pdf).
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GERMANY
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
Needle and syringe programmes were legalized in 1992, and substitution-based drug dependence 
treatment has been nationally regulated since 2001. Harm reduction is one of the four pillars of the 
national drug strategy.
DEPENALIZATION
Drug use is not a criminal offense, and since 1992 public prosecutors have had the option to refrain from 
prosecuting individual caught in possession of small quantities of drugs for personal use.   
POLICING
There are no criminal penalties or other sanctions for the possession of needle/syringes. Germany has 
the highest number of syringe vending machines in the world.
90 000 
PEOPLE WHO 
INJECT DRUGS
Sources: Robert Koch Institute. PRESSURE study: drugs and chronic infectious diseases in Germany - results of the pilot phase of a sero-and 
behavioral surveys among injecting drug users. Epidemiol Bull. 2012;33. 
Robert Koch Institute annual estimate (published in November 2011). 
Backmund M, Meyer K, Henkel C, Reimer J, Wachtler M, Schutz CG. Risk Factors and predictors of human immunodeficiency virus infection 
among injection drug users. Eur Addict Res. 2005;11:138-144.
Robert Koch Institute. Epidemiologisches Bulletin. 9. November 2015 /Nr. 45.
Bundeskriminalamt (BKA) (Hrsg.) (2006). Bundeslagebild Rauschgift 2004. BKA, Wiesbaden.
+
+
+
82.1%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
83 000
[64 000–103 000]
PEOPLE LIVING  
WITH HIV
4.7%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: EMCDDA, Country overview: Germany.
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Sources: German REITOX report 2015, Workbook Harms and Harm Reduction. 
REITOX Focal Point, 2014 National report to EMCDDA (2013 data). 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
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Source: Germany: 2015 national report (2014 data) to the EMCDDA by the Reitox National Focal Point. Workbook: prison. Hamm: 
Deutsche Hauptstelle für Suchtfragen; 2014 (http://www.dhs.de/fileadmin/user_upload/pdf/Reitox_Jahresberichte/WB09_Prison_2015_
Germany_EN.pdf).
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INDIA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
Amendments to the Narcotics Drug and Psychotropic Substance Act in 2014 enabled 
further scale-up of opioid substitution therapy, needle–syringe programmes and other harm 
reduction services.
CRIMINALIZATION
Use of cannabis can result in up to six months of imprisonment, and use of heroin, morphine 
or cocaine can result in up to one year of imprisonment.
POLICING
There are no criminal penalties or other sanctions for the possession of needle/syringes.
2%
ARE WOMEN 
AND GIRLS
177 000 
PEOPLE WHO 
INJECT DRUGS
Sources: Mapping and population size estimate, NACO, 2009. 
HIV Sentinel Surveillance in India, 2010–11. 
Integrated biological and behavioural survey, India, 2014–2015.
+
+
–
13.2%
OF PEOPLE WHO INJECT DRUGS LIVING WITH  
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
1 980 000
[1 627 000–2 472 
000]
PEOPLE LIVING  
WITH HIV
9.9%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: UNAIDS country office report, 2016.
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HARM REDUCTION
54%
used sterile  
equiptment at last 
injection
22 000
people enrolled in opioid 
substitution therapy
240
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
86.5%
tested for HIV and 
received the result 
within the last  
12 months
77%
used a condom  
during last risky sex
Sources: Integrated biological and behavioural survey, India, 2014–2015.
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting) 
National programme data, 2015.
NACO, unpublished calculations, based on integrated biological and behavioural survey, 2014–2015.
Sources: National commitments and policy instrument: part B - 2014 India. 
Medical care and hospital administration. Delhi: Government of NCT of Delhi, India; 2014 (http://www.delhi.gov.in/wps/wcm/connect/
lib_centraljail/Central+Jail/Home/Medical+Care+and+Hospital+Administration).
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INDONESIA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
National-level legislation was enacted in 2011 in support of harm reduction, including regulations that 
facilitate the diversion of drug users into drug treatment. 
CRIMINALIZATION
Possession of small quantities of drugs for personal use can result in heavy fines and lengthy prison sentences. 
Incarceration due to narcotics-related off ences accounts  for  about 37% of  the  total prison population.
HEALTH CARE
Health insurance regulations consider drug use a “self-inflicted” condition that can disqualify an individual 
from receiving health insurance benefits. The estimated coverage of antiretroviral treatment among people 
who inject drugs is 6%.
COMPULSORY DETENTION
There are 1300 people who use drugs in compulsory detention centres.
5.7%
ARE WOMEN 
AND GIRLS
36 000 
PEOPLE WHO 
INJECT DRUGS
+
–
–
37%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
641 000
[578 000–701 000]
PEOPLE LIVING  
WITH HIV
39.7%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
–
Source: UNAIDS country office report, 2016.
Indonesia National AIDS Commission. Global AIDS response progress reporting: Indonesia country progress report 2014. 
HIV mathematical modelling, 2014.
Sources: Size estimation report, Ministry of Health, Indonesia, 2015.
HIV Mathematical Modeling, 2014. 
Behavioural rapid survey among PWID (SCP Penasun 2014). 
Intregated Rapid Behaviour Survey of IDU and Sentinel Surveillance in Tanggerang, Denpasar and Makasar, 2014.
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HARM REDUCTION
87%
used sterile  
equiptment at last 
injection
2000
people actively enrolled in 
opioid substitution therapy
44
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
63%
tested for HIV and 
received the result 
within the last  
12 months
56%
used a condom  
during last risky sex
Sources: Integrated biological and behavioural survey, Indonesia, 2011. 
Quarterly report. Jakarta: Ministry of Health, Indonesia; 2015.
Sources: Global AIDS response progress reporting: Indonesia country progress report 2014. Jarkarta: Indonesia National AIDS 
Commission, 2014. 
Ditjenpas routine data. 
Quartely report. Jakarta: Ministry of Health, Indonesia; 2015.
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IRAN (ISLAMIC REPUBLIC OF)
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
Ministry of Health guidelines for methadone maintenance therapy have been available since 2002; 
buprenorphine maintenance treatment is also offered; opium tincture solution maintenance treatment 
has been delivered as a pilot project.
POLICING
There are no criminal penalties or other sanctions for the possession of needles and syringes.
3%
ARE WOMEN 
AND GIRLS
200 000 
[170 000–230 000]
PEOPLE WHO 
INJECT DRUGS
+
+
73 000
[51 000–113 000]
PEOPLE LIVING  
WITH HIV
13.8%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: UNAIDS country office report, 2016.
National AIDS Committee Secretariat, Ministry of Health and Medical Education, Islamic Republic of Iran AIDS progress report on 
monitoring of the United Nations General Assembly Special Session on HIV and AIDS, March 2015. Shahrbabaki ME et al., Methadone 
treatment in Iranian opiate addicts: a preliminary report, Addict Health 2011;3:53–60.
Sources: Rapid Situation Assessment, Iran, 2007. 
Spectrum files, 2015. 
Integrated biological and behavioural survey, Iran, 2014. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015. 
J Pak Med Assoc. 2014;64:134-137. 
Iran J Public Health. 2014;43:229-234.
Hepat Mon. 2012;12:442-447. 
Med Glas (Zenica). 2012;9:299-303. 
Hepat Mon. 2010;10:26-30.
Int J Infect Dis. 2010;14:e28-33.
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81.5%
used sterile  
equiptment at last 
injection
599 000
people enrolled in opioid 
substitution therapy
44–60
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
27.2%
tested for HIV and 
received the result 
within the last  
12 months
44.3%
used a condom  
during last risky sex
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: DG health of IPO, Iran. 2015. 
The global state of harm reduction 2014. London: Harm Reduction International; 2014 (http://www.ihra.net/files/2015/02/16/
GSHR2014.pdf).
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KAZAKHSTAN
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
A Republican AIDS Centre decree provides guidance on the delivery of a comprehensive package of 
HIV prevention, treatment and care of HIV for people who use drugs, including needle and syringe 
distribution; opioid substitution therapy remains a pilot programme.
CRIMINALIZATION
Non-medical use of narcotic drugs and psychotropic substances is punishable by fines, correctional 
labour and incarceration for 45 days.
DOMESTIC INVESTMENT
The Government of Kazakhstan is gradually replacing donor funding with domestic funding.
17%
ARE WOMEN 
AND GIRLS
128 000 
PEOPLE WHO 
INJECT DRUGS
Sources: Republican AIDS Centre M&E report, 2015. 
Electronic HIV Case Management System, data of the Republican AIDS Centre, 2014–2015. 
Integrated biological and behavioural survey, Kazakhstan, 2014.
+
+
–
6.8%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
20 000
[18 000–24 000]
PEOPLE LIVING  
WITH HIV
8.2%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: UNAIDS country office report, 2016.
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HARM REDUCTION
52.2%
used sterile  
equiptment at last 
injection
<1000
people enrolled in opioid 
substitution therapy
264
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
60.6%
tested for HIV and 
received the result 
within the last  
12 months
49.8%
used a condom  
during last risky sex
Sources: Republican AIDS Center M&E report, 2015. 
Integrated biological and behavioural survey, Kazakhstan, 2014. 
OST electronic register.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 (http://www.ihra.net/files/2015/02/16/
GSHR2014.pdf).
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KENYA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
The Kenyan National AIDS Control Council introduced a harm reduction strategy in 2011, and 
the Kenya AIDS Strategic Framework for 2015–2020 promotes the comprehensive package for 
harm reduction recommended by WHO, UNODC and UNAIDS.
POLICING
Police have discretionary powers in favour of harm reduction, but many continue to arrest and 
prosecute people who use drugs for the possession of drug paraphernalia.
CRIMINALIZATION
Possession of any illicit narcotic or psychotropic substance is a criminal offence punishable by 
a fine and/or imprisonment.
18.3%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
9%
ARE WOMEN 
AND GIRLS
18 000 
PEOPLE WHO 
INJECT DRUGS
+
–
–
1 207 000
[1 054 000–1 390 000]
PEOPLE LIVING  
WITH HIV
Source: UNODC, 2012. 
Rapid Situation Assessment for PWID, Kenya, 2012.
Sources: Kageha E, Drug laws and human rights in Kenya: disharmony in the law and training recommendations to law enforcement, 
Mainline 2015. 
UNAIDS country office report, 2016.
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HARM REDUCTION
89%
used sterile  
equiptment at last 
injection
-
tested for HIV and 
received the result 
within the last  
12 months
48%
used a condom  
during sex with a 
non-paying partner 
within the past 
month
1100
people enrolled in opioid 
substitution therapy
20
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
Sources: NASCOP Polling Booth Survey, 2015. 
National AIDS and STI Control Proramme, programme data, 2014–2016.
Sources: The global state of harm reduction 2014. London: Harm Reduction International; 2014 (http://www.ihra.net/files/2015/02/16/
GSHR2014.pdf). 
UNAIDS country office report, 2016.
* In some prisons, arrangements are made for people who use drugs who were enrolled in opioid substitution 
   therapy before their incarceration to continue treatment through daily visits to the local clinic. 
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KYRGYZSTAN
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
Harm reduction has been part of the national drug strategy since 2011.
CRIMINALIZATION
Possession of more than 1 gram of a narcotic drug is a criminal offence punishable by a fine and up to 
two years in prison; the fines for drug possession have been increased in recent years.
DOMESTIC INVESTMENT
The financing of harm reduction in this lower-middle-income country is highly reliant on external 
funding; only 16% of expenditure for needle and syringe distribution and opioid substitution therapy 
came from domestic sources in 2013.
12%
ARE WOMEN 
AND GIRLS
25 000 
PEOPLE WHO 
INJECT DRUGS
+
–
9000
[7000–12 000]
PEOPLE LIVING  
WITH HIV
26%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
Source: Size estimation report, Kyrgyzstan, 2013. 
Integrated biological and behavioural survey, Kyrgyzstan, 2013. 
Regional Advisory Committee, 2013.
–
Source: UNAIDS country office report, 2016.
45%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
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55%
used sterile  
equiptment at last 
injection
1227
people enrolled in opioid 
substitution therapy
252
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
43%
tested for HIV and 
received the result 
within the last  
12 months
39%
used a condom  
during last risky sex
Sources: Integrated biological and behavioural survey, Kyrgyzstan, 2013. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2014 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: Georg Fisher (GF) annual report, 2014. 
Annual report, 2014. AIDS Foundation East-West; 2014.
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MALAYSIA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
2%
ARE WOMEN 
AND GIRLS
170 000 
PEOPLE WHO 
INJECT DRUGS
+
–
–
100 000
[90 000–110 000]
PEOPLE LIVING  
WITH HIV
16.3%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
5.5%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
Sources: EPP, 2014. 
National monitoring and evaluation data, 1986–2014. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015.
Integrated biological and behavioural survey, Malaysia, 2014. 
Survey among MMT clients, 2014.
ENABLING NATIONAL POLICY
The country’s needle and syringe exchange programme and opioid substitution therapy are 
cornerstones of the national HIV prevention strategy.
POLICING
Section 37 of the Dangerous Drug Act 1952 states that possession of needles and syringes can result 
in up to two years in prison; a 2006 police standard operating procedure instructs police not to target 
needle and syringe exchange sites for arrest, but adherence to the standard operating procedure 
appears uneven.
COMPULSORY DETENTION
Under Malaysia’s drug control laws, anybody with a positive urine screen for narcotic drugs can be 
deemed to be drug dependent by a government medical officer and sent to a detention centre for 
compulsory treatment followed by community supervision following release.
Source: UNAIDS country office report, 2016; Global AIDS response progress report Malaysia, Ministry of Health, Malaysia, 2015. Kamarulzaman 
A, McBrayer J, Compulsory drug detention centers in East and Southeast Asia, Int J Drug Policy 2015;26:S33–S37. Rahman F, Parasuraman G, 
Police knowledge of needle-and-syringe programs and harm reduction in Malaysia, Sixth Annual Conference of the International Society for the 
Study of Drug Policy, Canterbury 30–31 May 2012, (https://docs.google.com/file/d/0B62R_9AekiRXR1VQRW5JZzVEU00/edit?usp=sharing).
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92.8%
used sterile  
equiptment at last 
injection
75 000
people enrolled in opioid 
substitution therapy
61
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
37.8%
tested for HIV and 
received the result 
within the last  
12 months
20.8%
used a condom  
during last risky sex
Sources: National programme monitoring and evaluation data, 1986–2014.
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Integrated biological and behavioural survey, Malaysia, 2014.
Source: Monitoring and evaluation data.
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2.5%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
MEXICO
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
DECRIMINALIZATION
In August 2009 Mexico’s federal government partially decriminalized possession of small quantities of 
drugs such as cannabis, cocaine, amphetamines and heroin.
POLICING
Policing practices such as crackdowns, targeted patrols of harm reduction services and syringe 
confiscation may reduce access to services and increase risky drug-related behaviours among people 
who inject drugs.
164 000 
PEOPLE WHO 
INJECT DRUGS
+
–
191 000
[139 000–265 000]
PEOPLE LIVING  
WITH HIVSources: National Survey of Addictions, Mexico, 2011. 
CENSIDA website, 2013. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: Mexico’s drug policy reform: cutting edge success or crisis in the making? Int J Drug Policy 2014;25:823–825.
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HARM REDUCTION
71.3%
used sterile  
equiptment at last 
injection
-
people enrolled in opioid 
substitution therapy
3.9
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
35%
tested for HIV and 
received the result 
within the last  
12 months
27.8%
used a condom  
during last risky sex
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: http://www.ihra.net/global-state-of-harm-reduction.
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MOROCCO
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
A national harm reduction plan guides implementation of needle and syringe distribution and opioid 
substitution therapy.
CRIMINALIZATION
Possession of small quantities of drugs is a criminal offence that is strictly enforced, with penalties 
including fines and up to one year in prison.
POLICING
There are no criminal penalties or other sanctions for the possession of needles, syringes or other drug 
paraphernalia.
8%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
10.4%
ARE WOMEN 
AND GIRLS
3000 
PEOPLE WHO 
INJECT DRUGS
+
+
–
28 000
[19 000–36 000]
PEOPLE LIVING  
WITH HIV
57%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
Modes of Transmission, Morocco, 2013. 
Spectrum files, 2014. 
Integrated biological and behavioural survey, Morocco, 2011–2012 and 2014–2015.
Source: UNAIDS country office report, 2016; Himmich H, The rise of harm reduction in Morocco: successes and challenges, Middle East 
Institute, 23 February 2015.
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HARM REDUCTION
<1000
people enrolled in opioid 
substitution therapy
88
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
23.3%
tested for HIV and 
received the result 
within the last  
12 months
31.8%
used a condom  
during last risky sex
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
National programme data, 2015.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
80%
used sterile  
equiptment at last 
injection
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MYANMAR
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
Harm reduction is included in the national strategic plan for HIV developed by the national AIDS 
programme under the Ministry of Health.
CRIMINALIZATION
The Narcotic Drugs and Psychotropic Substances Law (1993) makes little distinction between drug users 
and traffickers; penalties are severe and sentences are not proportional to crimes (e.g. 3–5 years in 
prison for “small time offenders”).
POLICING
Sections of a nearly 100-year-old excise act that made possession of needles and syringes illegal were 
repealed in 2015.
REGISTRATION OF DRUG USERS
The Narcotic Drugs and Psychotropic Substances Law (1993) establishes mandatory registration for drug 
treatment, undermining the strengthening of harm reduction interventions; failure to register for drug 
treatment can result in a prison sentence of up to five years.
28.5%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
<1–8%
ARE WOMEN 
AND GIRLS
83 000 
PEOPLE WHO 
INJECT DRUGS
+
+
–
–
202 000
[180 000–222 000]
PEOPLE LIVING  
WITH HIV
Sources: Integrated biological and behavioural survey among people who inject drugs, Myanmar, 2014. 
Population size estimation, Myanmar, 2014. 
AIDS Epidemic Model, 2014. 
’Zaw SK et al. Prevalence of hepatitis C and B virus among patients infected with HIV: a cross-sectional analysis of a large HIV care 
programme in Myanmar. Trop Doc. 2013;43:113-115
Source: UNAIDS country office report, 2016.
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10 000
people enrolled in opioid 
substitution therapy
168
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
86%
used sterile  
equiptment at last 
injection
22.2%
tested for HIV and 
received the result 
within the last  
12 months
22.9%
used a condom  
during last sex
Sources: Integrated biological and behavioural survey among people who inject drugs, Myanmar, 2014. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
National Drug Abuse Control Programme, Ministry of Health, 2015.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
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NIGERIA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
The National Policy for the Control of Viral Hepatitis in Nigeria, published in July 2015, calls for a 
combination approach to disease prevention among people who inject drugs, including needle–syringe 
exchange and opioid substitution therapy.
LACK OF SERVICES
There are currently no needle–syringe or opioid substitution therapy programmes in the country.
3.4%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
19 000 
PEOPLE WHO 
INJECT DRUGS
3 021 000
[2 719 000–3 331 000]
PEOPLE LIVING  
WITH HIV
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 (http://www.unaids.org/
en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Integrated Biological and Behavioral Surveys 2014.  Federal Ministry of Health, Nigeria.
Sources: The global state of harm reduction 2014, London, Harm Reduction International, 2014 (http://www.ihra.net/files/2015/02/16/
GSHR2014.pdf). 
National HIV/AIDS & STI Control Programme, Federal Ministry of Health, Nigeria. National Policy for the Control of Viral Hepatitis in Nigeria, 
July 2015.
+
–
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-
people enrolled in opioid 
substitution therapy
-
syringes distributed per person 
who inject drugs per year
0    
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
80%
used sterile  
equiptment at last 
injection
52.1%
tested for HIV and 
received the result 
within the last  
12 months
87.8%
used a condom  
during last risky sex
Sources: Integrated Biological and Behavioral Surveys 2014.  Federal Ministry of Health, Nigeria.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
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27.2%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
PAKISTAN
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
105 000 
PEOPLE WHO 
INJECT DRUGS
+
–
–
92 000
[56 000–178 000]
PEOPLE LIVING  
WITH HIV
1.5%
ARE WOMEN 
AND GIRLS 95.4%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
Sources: UNODC, 2013. 
Integrated biological and behavioural survey, Pakistan, 2011.
CRIMINALIZATION
Under the Controlled Narcotic Substances Act, possession of less than 100 grams of narcotic drugs or 
psychotropic substances is punishable by fines and up to two years in prison.
POLICING
The Controlled Narcotic Substances Act does not punish drug use per se, and the possession of needles 
and syringes or other drug paraphernalia is not objectionable.
REGISTRATION OF DRUG USERS
Provincial governments are required to register all people who use drugs within their respective 
jurisdictions.
DOMESTIC INVESTMENT
The financing of harm reduction in this lower-middle-income country is highly reliant on external funding, 
accounting for 72% of all funding in 2013.
Source: UNAIDS country office report, 2016.
–
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38.6%
used sterile  
equiptment at last 
injection
0
people enrolled in opioid 
substitution therapy
178
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
71.8%
tested for HIV and 
received the result 
within the last  
12 months
25.8%
used a condom  
during last risky sex
Sources: National AIDS Control Programme (NACP), Pakistan. 
Integrated biological and behavioural survey, Pakistan, 2011. 
Pakistan Global AIDS Response Progress Report (GARPR) 2015.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
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PHILIPPINES
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
The Philippine AIDS Prevention and Control Act of 1998 supports harm reduction and the provision of 
health and social services to people who use drugs.
CRIMINALIZATION
Possession of narcotic drugs for personal use is punishable by fines or imprisonment.
POLICING
Possession of needles, syringes or other drug paraphernalia can result in a fine and up to one year in 
prison.
COMPULSORY DETENTION
Detention and coercive treatment is currently the dominant approach to drug use and drug 
dependence.
44.9%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
+
–
–
35 000
[21 000–102 000]
PEOPLE LIVING  
WITH HIV
10%
ARE WOMEN 
AND GIRLS 83.6%
OF PEOPLE WHO INJECT DRUGS LIVING WITH
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
15 000 
[17 000–23 000]
PEOPLE WHO 
INJECT DRUGS
–
Sources: UNAIDS country office report, 2016. Transition from compulsory centres for drug users to voluntary community-based treatment 
and services, discussion paper for the Third Regional Consultation on Compulsory Centres for Drug Users in Asia and the Pacific, 21–23 
September 2015. Republic Act 8504 of 1998 (AIDS Law); Republic Act 9165 of 2002 (Dangerous Drugs Act).
Source: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
Presentation of EB (Partners Forum), 2015.
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HARM REDUCTION
-
people enrolled in opioid 
substitution therapy
-
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
6.7%
tested for HIV and 
received the result 
within the last  
12 months
12.9%
used a condom  
during last risky sex
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Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
Integrated biological and behavioural survey, Department of Health, Philippines, 2013.
Source: Department of Health, Philippines, 2015.
33%
used sterile  
equiptment at last 
injection
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PORTUGAL
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
17.1%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
+
+
68 000
[52 000–88 000]
PEOPLE LIVING  
WITH HIV
60%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
16 000 
PEOPLE WHO 
INJECT DRUGS
Source: EMCDDA, 2013.
ENABLING NATIONAL POLICY
Risk and harm reduction is a pillar of the National Plan Against Drugs and Drug Addictions 2013–20; 
a network of comprehensive harm reduction programmes has been consolidated throughout the 
country in critical zones of intensive drug use.
DECRIMINALIZATION
In 2000 Portugal passed a new drug law that downgraded the purchase, possession and consumption 
of small amounts of narcotic drugs from criminal to administrative offences; under the law an individual 
can possess a 10-day supply of drugs before facing criminal charges as a drug dealer.
POLICING
There are no criminal penalties or other sanctions for the possession of needles and syringes.
+
Source: Country overview: Portugal, Lisbon, European Monitoring Centre for Drugs and Drug Addiction. Domosławski A, Drug policy in 
Portugal: the benefits of decriminalizing drug use, Warsaw, Open Society Foundations, 2011 (https://www.opensocietyfoundations.org/sites/
default/files/drug-policy-in-portugal-english-20120814.pdf).
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HARM REDUCTION
17 000
people enrolled in opioid 
substitution therapy
150
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
-
used sterile  
equiptment at last 
injection
-
tested for HIV and 
received the result 
within the last  
12 months
-
used a condom  
during last risky sex
   HIV TESTING
   ANTIRETROVIRAL THERAPY
 
   CONDOMS
   NEEDLES AND SYRINGES
   OPIOID SUBSTITUTION THERAPY
Sources: EMCDDA, 2013. 
Serviço de Intervenção nos Comportamentos Aditivos e nas Dependências (SICAD), 2013.
Sources: Serviço de Intervenção nos Comportamentos Aditivos e nas Dependências (SICAD), 2013.
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REPUBLIC OF MOLDOVA
HIV EPIDEMIC*
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
A revised HIV law issued in 2012 contains specific clauses on harm reduction for people who use drugs in 
communities and prisons.
DECRIMINALIZATION
Simple drug use is an administrative offence according to Article 85 of the Administrative Offences Code 
passed in 2008; under the code, purchase or possession of narcotic drugs or psychotropic substances 
in small amounts without the purpose of distribution, as well as their consumption without a medical 
prescription, is sanctioned with a fine.
REGISTRATION OF PEOPLE WHO USE DRUGS
A positive drug test conducted at the request of police or by an individual voluntarily accessing the 
health-care system can result in registration into a narcological register database.
30 000 
PEOPLE WHO 
INJECT DRUGS
+
–
17 000
[15 000–21 000]
PEOPLE LIVING  
WITH HIV
Source: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015  
Investment case, Support to perform the HIV epidemiological situation analysis, Chisinau, 2015. 
Integrated biological and behavioural survey, Moldova, 2012.
* HIV and HCV prevalence data for people who inject drugs 
   in Chisinau, the capital of the Republic of Moldova.
+
Source: UNAIDS country office report, 2016. EMCDDA, Country overview: Moldova.
8.5%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
17%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
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HARM REDUCTION*
<1000
people enrolled in opioid 
substitution therapy
67.5
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
   HIV TESTING
   ANTIRETROVIRAL THERAPY
 
   CONDOMS
   NEEDLES AND SYRINGES
   OPIOID SUBSTITUTION THERAPY
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
Integrated biological and behavioural survey, Moldova, 2012.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
25.9%
used a condom  
during last risky sex
99.4%
used sterile  
equiptment at 
last injection
47.3%
tested for HIV and 
received the result 
within the last  
12 months
* Behaviour data is for Chisinau, the capital of the Republic of Moldova.
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RUSSIAN FEDERATION
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
15.6%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
–
–
–
1 070 000
[900 000–1 275 000]
PEOPLE LIVING  
WITH HIV
Source: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Interview with the Chairman of the State Anti-Drug Committee, Federal Drug Control Service Director Viktor Ivanov, 28 December 2015. 
Federal Drug Control Service [website] (http://www.fskn.gov.ru/includes/periodics/events_right/2015/1228/142041939/detail.shtml, 
accessed 11 APril 2016). 
UNODC/UNAIDS/WHO 2015 size estimates. 
INSUFFICIENT ENABLING POLICY
The country’s policy framework does not have explicit supportive reference to harm reduction, and 
opioid substitution therapy is not available in the country.
CRIMINALIZATION
Drug use is an administrative offence punishable by a fine of 4000–5000 roubles or up to 15 days 
incarceration; possession of drugs can be an administrative or criminal offence depending on the 
amount in possession (Section 228 of the Criminal Code of the Russian Federation).
POLICING
Syringe possession is not illegal, and needle and syringe programmes exist; however, cases of arrests 
for possession of needles and syringes have been documented in some cities.
Sources: The global state of harm reduction 2014, London, Harm Reduction International, 2014 (http://www.ihra.net/files/2015/02/16/
GSHR2014.pdf). Lunze K, Raj A, Cheng DM, Quinn EK, Bridden C, Blokhina E, et al., Punitive policing and associated substance use risks 
among HIV-positive people in Russia who inject drugs, J Int AIDS Soc, 2014, 17, 19043; UNAIDS Regional Support Team report, 2016.
1 500 000 
PEOPLE WHO 
INJECT DRUGS
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HARM REDUCTION
-
people enrolled in opioid 
substitution therapy
-
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
   HIV TESTING
   ANTIRETROVIRAL THERAPY
 
   CONDOMS
   NEEDLES AND SYRINGES
   OPIOID SUBSTITUTION THERAPY
72.6%
used their own 
needle/syringe at 
last injection
48.7%
tested for HIV and 
received the result 
within the last  
12 months
55.6%
used a condom  
during last sex
Source: Yakovleva A. Evaluation of quality and effectiveness of regional low threshold harm reduction projects for IDUs, analytical report.  
ESVERO , 2014.
Source: UNAIDS Regional Support Team report, 2016.
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SOUTH AFRICA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
14%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
75 000 
PEOPLE WHO 
INJECT DRUGS
–
6 498 000
[6 139 000–7 117 000]
PEOPLE LIVING  
WITH HIV
CRIMINALIZATION
Possession of narcotic drugs for personal use is punishable by fines or imprisonment.
POLICING
Awareness of harm reduction among law enforcement is low, leading to discouraging practices such as 
confiscation of needles and syringes; two thirds of people who inject drugs who were surveyed during 
a formative assessment in two metropolitan areas reported their engagement with law enforcement as 
being “abusive”.
Sources: National strategic plan on HIV, STIs and TB 2012–2016, Pretoria, South African National AIDS Council, 2011. Scheibe A et al., A long 
walk to freedom: towards health and rights for people who inject drugs in South Africa, TB/HIV Care Association, OUT LGBT Wellbeing, 2016 
Lambert, A. Harm Reduction in South Africa. HIV and Drug Use Pre-Conference. Durban; TB/ HIV Care Association: 2015.
–
Sources: HIV positive drug users are harassed daily by police and gangsters. Times Live, 2016 (http://www.timeslive.co.za/
local/2016/02/03/HIV-positive-drug-users-are-harassed-daily-by-police-and-gangsters accesed on 23/03/2016). 
Scheibe A, Makapela D, Brown B, dos Santos M, Hariga F, Virk H, et al. HIV prevalence and risk among people who inject drugs in five 
South African cities. Int J Drug Policy. 2016; http://dx.doi.org/10.1016/j.drugpo.2016.01.004.
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HARM REDUCTION
178
people enrolled in opioid 
substitution therapy
6
syringes distributed per person 
who inject drugs per year
0    
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
50%
used a condom  
during last risky sex
Sources: UNAIDS country office report, 2016.
United Nations Office on Drugs and Crime. (2015). Rapid assessment of HIV and related risk factors among people who inject drugs from five 
South African cities. Final report. Pretoria: UNODC.
http://www.groundup.org.za/article/medicine-offers-hope-heroin-users-mitchells-plain/. 
Scheibe A, Makapela D, Brown B, dos Santos M, Hariga F, Virk H, et al. HIV prevalence and risk among people who inject drugs in five South 
African cities. Int J Drug Policy. 2016; http://dx.doi.org/10.1016/j.drugpo.2016.01.004.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf). UNAIDS country office report, 2016.
51%
used sterile  
equiptment at last 
injection
55%
tested for HIV and 
received the result 
within the last  
12 months
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THAILAND
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
In 2014 the national narcotics control board launched a new harm reduction strategy that calls for 
collaboration between government agencies and civil society in the delivery of services, and the National 
AIDS Committee has endorsed the policy and strategies on harm reduction for drug use.
CRIMINALIZATION
Under the 1979 Illicit Drug Act, substance use is a criminal offence; consumption of small amounts of type 
1 substances, such as heroin, is punishable by fines and up to three years in prison.
POLICING
Since 2003, there have been periodic police crackdowns on people who use drugs. 
COMPULSORY DETENTION
In 2014, 96 680 people arrested for drug use were placed in compulsory detention; a recent revision to 
the national drug policy (Order No. 108/2014) aims to enrol more people who use drugs in voluntary drug 
dependence treatment provided by public health services.
21%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
+
–
–
446 000
[390 000–660 000]
PEOPLE LIVING  
WITH HIV
71 000 
PEOPLE WHO 
INJECT DRUGS
Sources: National Consensus Meeting: size estimation on PWID, National AIDS Management Centre, MOPH, September 2015.
Minutes, AIDS Epidemic Model Meeting, 2015.
Integrated biological and behavioural survey, Thailand, 2009/2010/2012/2014.  
AIDS Epidemic Model, 2010. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
–
Source: UNAIDS country office report, 2016; Windle J, Drugs and drug policy and Thailand, Brookings Institution, Center for 21st Century 
Security and Intelligence, 2015. The Third Regional Consultation on Compulsory Centres for Drug Users (CCDUs) in Asia and the Pacific, 21-
23 September 2015 Philippines, Office of the Narcotics Control Broad (ONCB).
115
HARM REDUCTION
5956
people enrolled in opioid 
substitution therapy
14
syringes distributed per person 
who inject drugs per year
0    
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
95.3%
used sterile  
equiptment at last 
injection
61.3%
tested for HIV and 
received the result 
within the last  
12 months
51.2%
used a condom  
during last risky sex
   HIV TESTING
   ANTIRETROVIRAL THERAPY
 
   CONDOMS
   NEEDLES AND SYRINGES
   OPIOID SUBSTITUTION THERAPY
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2016. 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: Department of Correction, 2015. 
Thailand NFM concept note, 2014. 
Thailand national operation plan: accelerating ending AIDS (2015–2019). Nonthaburi: National AIDS Management Center; 2014.
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UKRAINE
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
19.7%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
+
+
–
–
223 000
[211 000–263 000]
PEOPLE LIVING  
WITH HIV
54.9%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
310 000 
PEOPLE WHO 
INJECT DRUGS
23.6%
ARE WOMEN 
AND GIRLS
ENABLING NATIONAL POLICY
Needle and syringe distribution and opioid substitution therapy are supported by the Law on the 
National AIDS Programme for 2014–2018.
CRIMINALIZATION
In 2010 the threshold amounts between administrative and criminal charges for opioid drug possession 
were lowered; nongovernmental organizations believe this intensified criminalization of small amounts of 
drugs negatively affects the performance of harm reduction programmes.
POLICING
There are no criminal penalties or other sanctions for the possession of needles, syringes or other drug 
paraphernalia.
DOMESTIC INVESTMENT
The financing of harm reduction in this lower-middle-income country is almost completely reliant on 
international assistance.
Source: UNAIDS country office report, 2016; Country overview: Ukraine, European Monitoring Centre for Drugs and Drug Addiction.
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
Integrated biological and behavioural survey, Ukraine, 2013. 
Ukrainian Centre for Dangerous Deseases Control, 2013–15.
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HARM REDUCTION
8407
people enrolled in opioid 
substitution therapy
66
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
   HIV TESTING
   ANTIRETROVIRAL THERAPY
 
   CONDOMS
   NEEDLES AND SYRINGES
   OPIOID SUBSTITUTION THERAPY
96.9%
used sterile  
equiptment at last 
injection
42.8%
tested for HIV and 
received the result 
within the last  
12 months
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
Integrated biological and behavioural survey, Ukraine, 2013. 
Ukrainian Center for Socially Dangerous Disease, Ministry of Health, Ukraine, 2013–2015.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
48%
used a condom  
during sex with a 
non-paying partner 
within the past 
month.
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UNITED REPUBLIC OF TANZANIA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
15.5%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
30 000 
PEOPLE WHO 
INJECT DRUGS
+
1 477 000
[1 211 000–1 779 
000]
PEOPLE LIVING  
WITH HIV
ENABLING NATIONAL POLICY
Small-scale harm reduction services such as syringe distribution, bleach kits for decontamination and 
methadone maintenance therapy are being implemented through the national AIDS response.
Source: Global AIDS response country progress report, Government of the United Republic of Tanzania, 2014.
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
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HARM REDUCTION
3376
people enrolled in opioid 
substitution therapy
155
syringes distributed per person 
who inject drugs per year
0    
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
84.2%
used sterile  
equiptment at last 
injection
21.9%
tested for HIV and 
received the result 
within the last  
12 months
-
used a condom  
during last risky sex
Sources: UNAIDS country office report, 2016. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting).
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
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UNITED STATES OF AMERICA
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
3.6%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
+
+
–
1 322 000
[458 000–2 364 000]
PEOPLE LIVING  
WITH HIV
ENABLING NATIONAL POLICY
The Consolidated Appropriations Act of 2016 gives states and local communities the opportunity to use 
federal funds to support certain components of needle–syringe programmes.
CRIMINALIZATION
Possession of narcotic drugs for personal use is often punishable by fines or imprisonment; penalties vary 
by state.
OVERDOSE TREATMENT
By September 2015, 43 of 50 states had passed legislation to provide naloxone to people who are likely 
to witness an overdose, including family members and caregivers of people who use drugs.
Source: United States Congress, Consolidated Appropriations Act, 2016;
Davis CS, Carr D, Legal changes to increase access to naloxone for opioid overdose reversal in the United States, Drug Alcohol Depend 
2015, 157, 112–120.
Sources: Lansky A, Finlayson T, Johnson C, Hotzman D, Wejnert C, et al. Estimating the number of persons who inject drugs in the United 
States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS ONE.2014;9:e97596. 
CDC, HIV Monitoring Report, 2013. 
CDC, HIV and viral hepatitis fact sheet, March 2014.
800 000 
PEOPLE WHO 
INJECT DRUGS
80%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
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HARM REDUCTION
382 237
people enrolled in opioid 
substitution therapy
59
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS*
   HIV TESTING
   ANTIRETROVIRAL THERAPY
 
   CONDOMS
   NEEDLES AND SYRINGES
   OPIOID SUBSTITUTION THERAPY
35%
used sterile  
equiptment within 
the past 12 months
25.3%
used a condom  
during last sex
Sources: CDC HIV Monitoring Report, 2013. 
CDC Morb Mortal Wkly Rep. 2013;64. 
National HIV Behavioural Surveillance, USA, 2012. 
National Behavioural Health Barometer, SAMHSA, 2015. 
National Survey of Substance AbuseTreatment Services (N-SSATS), SAMHSA, 2013.
Source: Detoxification of chemically dependent inmates. Washington, DC: Federal Bureau of Prisons; 2014 (https://www.bop.gov/
resources/pdfs/detoxification.pdf). 
Management of HIV Infection, Federal Bureau of Prisons, Clinical Practice Guidelines, July 2013.
* Service availability is for federal prisons.
50.6%
tested for HIV and 
received the result 
within the last  
12 months
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UZBEKISTAN
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
48 000 
PEOPLE WHO 
INJECT DRUGS
+
–
30 000
[24 000–37 000]
PEOPLE LIVING  
WITH HIV
7.3%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
10.1%
ARE WOMEN 
AND GIRLS
ENABLING NATIONAL POLICY
There is explicit supportive reference to harm reduction in national policy documents, but opioid 
substitution therapy is unavailable.
CRIMINALIZATION
Possession of small quantities of drugs is punishable by fines and incarceration, starting from one to two 
times the minimum salary or 15 days of incarceration.
REGISTRATION OF DRUG USERS
Under a 2005 Ministry of Health order, people diagnosed with drug dependence are registered in 
a narcological register database; individuals are subject to regular medical check-ups and dynamic 
observation in outpatient substance abuse treatment units; exclusions apply to people who apply 
voluntarily for anonymous drug treatment.
Source: The global state of harm reduction 2014, London, Harm Reduction International, 2014 (http://www.ihra.net/files/2015/02/16/GSHR2014.
pdf). Country overview: Uzbekistan, European Monitoring Centre for Drugs and Drug Addiction. UNAIDS country office report, 2016.
–
Sources: Most-at-risk population size estimation report, Uzbekistan, 2012. 
Integrated Bio Behavioural Survey, Uzbekistan, 2014. 
Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 (http://www.unaids.org/en/
dataanalysis/knowyourresponse/globalaidsprogressreporting).
123
HARM REDUCTION
80%
used sterile  
equiptment at last 
injection
0
people enrolled in opioid 
substitution therapy
127.5
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
30%
tested for HIV and 
received the result 
within the last  
12 months
47%
used a condom  
during last risky sex
Sources: Global AIDS response progress reporting. Geneva: Joint United Nations Programme on HIV/AIDS; 2015 
(http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting). 
Integrated biological and behavioural survey, Uzbekistan, 2014.
Source: The global state of harm reduction 2014. London: Harm Reduction International; 2014 
(http://www.ihra.net/files/2015/02/16/GSHR2014.pdf).
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VIET NAM
HIV EPIDEMIC
LEGAL AND POLICY ENVIRONMENT
ENABLING NATIONAL POLICY
The Law on HIV/AIDS Prevention and Control authorizes harm reduction, including the provision of needles 
and syringes, peer outreach support and methadone maintenance therapy.
POLICING
There are no criminal penalties or other sanctions for the possession of needles, syringes or other drug 
paraphernalia.
CRIMINALIZATION
Possession of small quantities of drugs for personal use is a criminal offence punishable by up to five years 
in prison.
COMPULSORY DETENTION
For most of the past 20 years, the primary approach to drug dependence treatment has been compulsory 
detention within centres, which has raised serious human rights concerns; in recent years, as methadone 
maintenance therapy has scaled up, the number of people in compulsory detention has decreased.
272 000 
PEOPLE WHO 
INJECT DRUGS
+
+
–
–
245 000
[220 000–275 000]
PEOPLE LIVING  
WITH HIV
Source: AIDS Epidemic Model, Viet Nam, 2014.  
Integrated biological and behavioural survey, Viet Nam, 2009.  
HIV sentinel surveillance, Viet Nam, 2015.
Source: UNAIDS country office report, 2016.
9.3%
OF PEOPLE WHO INJECT 
DRUGS ARE LIVING WITH HIV
26.8%
OF PEOPLE WHO INJECT DRUGS LIVING WITH 
HIV ARE COINFECTED WITH HEPATITIS C VIRUS
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HARM REDUCTION
44 000
people enrolled in opioid 
substitution therapy
62
syringes distributed per person 
who inject drugs per year
0
safe injecting  
facilities
SERVICES AVAILABLE IN PRISONS
38.1%
used a condom  
during last sex
96.4%
used sterile  
equiptment at last 
injection
Sources: National programme data, 2015. 
HIV sentinel surveillance plus behavioural survey (HSS+), Viet Nam, 2015.
Source: VAAC’s report on HIV/AIDS activities in 2015 and key tasks in 2016.
30.3%
tested for HIV and 
received the result 
within the last  
12 months
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